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Abstract
The proto-oncogene Akt/protein kinase B plays a pivotal role in cell
growth and survival. Phosphorylation of Akt at Thr308 and Ser473 activates the
kinase following growth factor stimulation. Delineating specific role of each
activation site in Akt1 on kinase activation, inhibition and substrate selection
remain elusive.
We designed a unique set of tools, relying on genetic code expansion with
phosphoserine and in vivo enzymatic phosphorylation, to produce differentially
phosphorylated Akt1 variants. We found that having both sites phosphorylated
increased the apparent catalytic rate of the enzyme by 1500-fold relative to the
unphosphorylated

enzyme.

This

increment

was

mainly

due

to

the

phosphorylation of Thr308 but not Ser473 which was confirmed via live cell
imaging. We further found that the traditional use of phosphomimetics was
unable to mimic the effect of p-Thr308 in the test tube and in cells.
Akt1 activity is also regulated via interactions between the kinase domain
and the N-terminal auto-inhibitory pleckstrin homology (PH) domain. Using the
same

strategy,

we

produced

Akt1

variants

containing

programmed

phosphorylation to probe the interplay between Akt1 phosphorylation status and
the auto-inhibitory function of the PH domain. Deletion of the PH domain
increased the enzyme activity for all three Akt1 phospho-variants. For the doubly
phosphorylated enzyme, deletion of the PH domain relieved auto-inhibition by
295-fold. The robustly active PH domain deleted enzyme variants were used in
enzyme inhibition and substrate selectivity studies.

We found that

phosphorylation at Ser473 provided resistance to chemical inhibition by the Akt
inhibitor Akti-1/2.
ii

Finally, we used both defined and randomized peptide libraries to map
the substrate selectivity of singly and doubly phosphorylated Akt1 variants. The
data revealed that each phospho-form of Akt1 has distinct substrate
requirements. Surprisingly, phosphorylation of Ser473 in the context of a
pAkt1T308 enzyme led to increased activity on some, but not all Akt1 substrates.
We also verified a new Akt1 target as the terminal nucleotidyltransferase
(germline development 2) Gld2.
In conclusion, the site-specifically phosphorylated Akt1 variants that we
produced

enabled

in

characterizing

phosphorylation-dependent

activity,

inhibition and substrate selectivity of the oncogenic kinase Akt1. Since
phosphorylation status of Akt1 is used as a cancer biomarker, these variants can
act as indispensable tools in further characterizing downstream oncogenic
pathways and screening potential drug candidates.

Key words: Akt, Akti1/2 inhibitor, genetic code expansion, kinase, peptide
libraries, PH domain, phosphorylation
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Chapter 1
1 Introduction
1.1 Protein kinase B (Akt)
Murine oncogene v-AKT was initially identified from an Akt8
transforming retrovirus in spontaneous thymomas of high leukemic mice (1).
Later three groups independently characterized the cellular homolog of v-AKT.
These initial studies referred to the same kinase by different names: c-Akt (2),
related to A and C (RAC) kinase (3) or protein kinase B (PKB) since it showed
close similarity to protein kinase A and C (4). Akt was found to be a protein
kinase that phosphorylated multiple protein substrates involved in cell survival
signaling (5).
There are three isozymes of Akt found in mammalian cells: Akt1/PKBα,
Akt2/PKBβ, Akt3/PKBγ (Figure 1.1). Isozymes 1 and 2 are ubiquitously expressed
in all tissues while isozyme 3 is predominantly found in brain and testis (6).
Recent studies conducted on Akt isozyme specific knock-out mice revealed that
the isozymes contribute to functional diversity of Akt. Akt1 null mice suffered
from growth retardation and increased apoptosis (7). When Akt2 was knocked
out, mice suffered from type 2 diabetes related complications (8). Akt3 null mice
had impaired brain development (9). The cellular mechanism related to
differential activity of these isozymes is still not well established.
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1.2 Akt structure
All three isozymes of Akt share ~80% sequence identity and extensive
structural similarity. Akt is composed of three functional domains: 1) the Nterminal pleckstrin homology domain (PH domain); 2) the kinase or catalytic
domain; and 3) the small C-terminal regulatory domain referred to as the
hydrophobic motif (HM) (Figure 1.1). Akt1 is known to be activated by
phosphorylation at two key sites (5), Thr308 in the catalytic domain and Ser473 in
the hydrophobic motif.
The PH domain was named after the pleckstrin protein, which is a major
substrate of protein kinase C in platelets, lymphocytes, macrophages and
monocytes (10). All three Akt isozymes possess an N-terminal PH domain. In its
inactive confirmation, the PH domain is settled in between the N- and C-terminal
lobes of the kinase domain, which inhibits Akt activation by upstream kinase
phosphorylation (11,12). Solution phase hydrogen/deuterium (H/D) exchange
coupled with mass spectrometry analysis revealed that four β sheets (β1, β2, β5,
β6) of the PH domain bear positively charged residues that are readily available
for solvent accessibility in the inactive state and, which also makes it easier to
bind with the negatively charged lipid membrane. This indicates that the
conformation of the PH domain facilitates membrane binding (13) which is
important for Akt1 activity in cells (see Section 1.3). Binding of the PH domain
with phosphatidylinositols in the plasma membrane and endomembranes
releases the auto-inhibitory effect of the PH domain. Akt1 lacking a PH domain
shows higher activity compared to the full-length enzyme (14,15). A mutational
screen of the PH/kinase domain interface showed that Akt can be activated by
disruption of this interface interactions in cells. Some of these mutations

3
(Leu52Arg of PH domain, Asp323His of kinase domain) were demonstrated in
human cancers. Both mutations cause cellular transformation and are oncogenic
in vivo (16).
Structurally, the kinase domain of Akt is bilobal. The N terminal lobe is
comprised of 5 β sheets and a partially ordered αC helix. There is a deep cleft in
between the two lobes (17).
In the inactive state, certain regions of the Akt1 active site exist in a
disordered state. The disordered region of the N-terminal lobe transforms into an
ordered state following Thr308 phosphorylation (17,18). Hydrogen bond
formation between the phosphate group and Arg273 and Lys297 are facilitated
when Thr308 is phosphorylated. The hydrophobic interaction of the g-methyl
group of Thr308 with Cys310 is essential to establishing this hydrogen-bonding
network.
The C-terminal hydrophobic motif includes the Ser473 phosphorylation
site. Many studies suggest that full activation of the kinase requires
phosphorylation at both Thr308 and Ser473 (5). Once phosphorylated at Ser473
the hydrophobic motif interacts with the kinase domain and facilitates
disordered to ordered transition of the αC helix of the kinase domain (18).

4

Figure 1.1 Domain structure and regulatory phosphorylation sites in Akt
isozymes. The N-terminal pleckstrin homology (PH) domain, kinase domain
with the activation site Thr308 and hydrophobic motif (HM) with the activation
site Ser473 are shown. The homologous phosphorylation sites in Akt2 and Akt3
are noted.

1.3 Regulation of Akt1 activity
1.3.1 Phosphorylation-dependent activation of Akt
Akt1 is a major kinase in the phosphoinositide 3-kinase (PI3K)/Akt1
signaling pathway, which controls cell growth and survival (5). The impact of
active Akt on cell survival occurs mainly via inhibiting the activity of its
downstream targets as a result of phosphorylation. The activation of the Akt
enzyme occurs in response to growth factors (GF), insulin, or cytokine mediated
stimulation (20,21). GFs bind to receptor tyrosine kinases (RTK) in the plasma
membrane. This leads to PI3K activation via three independent pathways: i) Once
GFs bind to RTKs, the receptor kinases dimerize and auto-phophosphorylate
tyrosine residues. Upon phosphorylation, the p85 subunit of PI3K will bind to
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RTKs and this will lead to the activation of the p110 catalytic subunit of PI3K (22).
ii) The next pathway of PI3K activation occurs through the effector protein
growth factor receptor bound protein (GRB2). GRB2 is phosphorylated by
activated RTKs (23). GRB2 also binds to the p85 subunit of PI3K, contributing to
PI3K activation. iii) The third mode of activation is via RAS. RAS directly
activates the p110 catalytic subunit of PI3K independent of p85 (24). PI3K then
phosphorylates its immediate downstream target, a lipid second messenger in
the plasma membrane, phosphatidylinositol-4, 5-bisphosphate (PIP2), converting
PIP2 into phosphatidylinositol-4, 5-triphosphate (PIP3). PH domain containing
proteins like Akt1 and PDK1 bind to PIP3 with high affinity (25) (Figure 1.2).
In Akt1, upon PH domain binding to PIP3, the auto-inhibitory effect of PH
domain is released, exposing the activation sites for phosphorylation (5) by the
up-stream kinases, mechanistic target of rapamycin complex 2 (mTORC2) (26)
and PDK1 (27). mTORC2 is the Ser473 kinase and PDK1 phosphorylates Thr308
in Akt1.
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PIP3

PIP3

PIP3

PH

PH

PH-In (inhibited)

Akt1

PH
T308

Akt1
T308

PH-Out

Akt1
S473

S473

T308

S473

pAkt1S473
~10% activity
PDK1

mTORC2

Figure 1.2: Akt1 activation via phosphorylation at sites Thr308 and Ser473. The
upstream kinase for the Thr308 phosphorylation is phosphoinositide dependent
kinase 1 (PDK1). Complete activation of Akt1 requires C terminal Ser473
phosphorylation. mTORC2 phosphorylates Ser473.

PDK1 is an AGC family of kinase related to Akt. Phosphorylation at
Ser241 is essential for PDK1 activation. This is achieved through autophosphorylation and this leads to constitutively active enzyme in cell (28). The
level of PDK1 phosphorylation does not change upon stimulation of the cells
with insulin-like growth factors (29). PDK1 bears a PH domain which facilitates
its binding to PIP2 and PIP3. Interestingly, PDK1 also activates kinases that lack
PH domains, e.g., p70 ribosomal S6 kinase, p90 ribosomal S6 kinase. Instead,
these kinases carry PDK1 docking sites in their C-terminal hydrophobic motifs
(28).
mTORC2 is active as an effector protein upon growth factor and insulin
mediated PI3K activation. The Sin1 subunit of mTORC2 includes a PH domain,
which facilitates binding with PIP3 and co-localization with Akt (30). As with

p
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Akt, upon PIP3 binding the auto-inhibition of Sin1 is released leading to the
activation of mTORC2. mTORC2 is also responsible for phosphorylating the turn
motif at Thr450 which leads to stabilization of newly synthesized Akt (31).
Since Cohen’s group discovered PDK1 for the first time in 1997 (32), no
other kinase has been reported-as a potential phosphorylating agent for Thr308
(27,32). PDK1 was originally extracted from rabbit skeletal muscle. Once Akt was
incubated with this novel kinase PDK1, the level of phosphorylation and enzyme
activity of Akt is increased. Since PDK1 activity was dependent on PIP3
concentration

in

activity

assays,

they

named

this

novel

kinase

as

phosphoinositide dependent kinase or PDK1 (32). The kinase for Ser473 was
debated during earlier studies. Integrin-linked kinase (ILK) (33), mechanistic
target of rapamycin complex (mTORC2) (26) and autophosphorylation by Akt
itself (34) are among the possibilities for Ser473 phosphorylation. mTORC2
activation is now considered as the major route to Ser473 phosphorylation
because the rictor-mTOR complex directly phosphorylates full length Akt1 in
vitro, in Drosophila and human cells (26). Knocking down rictor or mTOR
decreases Akt1 phosphorylation significantly at Ser473 in several cell lines
including HEK293T, PC3 and HeLa (26).
Once phosphorylated, Akt1 in its active confirmation is released to the
cytosol and nucleus to phosphorylate its substrates. According to live cell
imaging studies using a Förster resonance energy transfer (FRET) based reporter
system developed for Akt1 (B kinase reporter, BKAR), active Akt1 was present in
the cytosol up to 10 min after growth factor stimulation (35). Akt1-dependent
phosphorylation of perhaps as many as 100 substrates is known to occur in the
cytosol (36) and nucleus (37). Fork head box O (FOXO) transcription factors are a
group of well-known Akt substrates and FOXOs can be phosphorylated by Akt1
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either in the cytosol or in the nucleus (38,39). Akt phosphorylation can direct
trafficking of β-catenin in different cellular locations to the cytosol and nucleus
(40). A recent study concluded that Akt1 is de-phosphorylated on a time scale of
10 minutes following its dissociation from the membrane (41). Although this
study indicated that Akt1 activity may be restricted to the plasma membrane
(41),

multiple

independent

reports

suggest

Akt1-dependent

substrate

phosphorylation occurs on the time scale of seconds to minutes in different subcellular compartments (5,35,36).

1.3.2 Phosphatase-dependent deactivation of Akt1
Akt1 is deactivated following dephosphorylation of the lipid second
messenger PIP3 by a lipid phosphatase, i.e., phosphatase and tensin homolog
(PTEN) (42). PTEN was initially identified as a tumor suppressor gene. Its
presence at the human chromosome 10q23.3 makes it highly susceptible to
genetic alteration in human cancers (43). PTEN de-phosphorylates multiple
substrates including tyrosines in proteins and lipids second messengers, e.g.,
PIP3. Further PTEN acts as a scaffolding protein in both the nucleus and
cytoplasm. Loss of function of PTEN leads to high plasma concentrations of PIP3
and constitutively active Akt isozymes (44,45). Other than Akt mediated cellular
functions, PTEN regulates the activation of c-Jun-N-terminal kinase (JNK)
pathway, which regulates cell proliferation, embryonic development and
apoptosis (46).
Specific phosphatases are known to dephosphorylate the regulatory sites
in Akt1. Thr308 is dephosphorylated by protein phosphatase 2A (PP2A) (47,48).
PP2A activity is highly regulated by a multiple regulatory subunits, which
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determine the substrate specificity of this phosphatase. The catalytic subunit and
the regulatory subunit A comprise the core structure of the phosphatase. The
third regulatory subunit B varies depending on the functionality (47). The
regulatory subunit B56 of PP2A recruits PP2A to Akt1 and de-phosphorylates
Thr308 specifically (48). Other than cell cycle regulation and apoptosis, PP2A
activity in maintaining cell adhesion and cytoskeleton maintenance are also
established (49). PP2A is a tumour suppressor protein. Loss of activity of PP2A is
associated with the onset of lung carcinoma and melanoma (50).
Phosphatases acting on Ser473 are the PH domain leucine-rich repeat
protein

phosphatases,

PHLPP1

and

PHLPP2.

Other

AGC

kinases

dephosphorylated by PHLPP family members include p70S6 kinase (S6K) and
protein kinase C (PKC). PHLPP is also capable of suppressing histone
phosphorylation to down regulate gene expression of RTKs (51).
A knockdown study revealed that p27 phosphorylation by Akt3 is
regulated by PHLPP2. In breast cancer cells, knockdown of PHLPP2 increased
p27 phosphorylation and knockdown of Akt3 decreased p27 phosphorylation.
Knocking down of either isoform of PHLPP decreased the phosphorylation of
Akt1 substrates, such as FOXO1 (52). This study concluded that PHLPP isoforms
de-phosphorylate Akt in an isozyme dependent manner: PHLPP1 dephosphorylates pSer473 of Akt isozymes 2 and 3 and PHLPP2 dephosphorylates
pSer473 in Akt1 and Akt3 (52).
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1.4 Additional post-translational modifications regulate
Akt1
Apart from the two activation sites Thr308 and Ser473, independent
studies have identified 25 additional phosphorylation sites on Akt1 (Figure 1.3).
Thr450, which is found in the turn-motif is constitutively phosphorylated by
mTORC2 (53). Phosphorylation of Thr450 enhances proper folding and stability
of Akt1 by preventing ubiquitin-dependent degradation of the kinase (54).
Ser124 was also identified as constitutively phosphorylated in different cell lines
including HEK293 cells, (55) BT74 cell lysates (56) and HTC116 (57,58). There are
23 other phospho-sites identified in proteomic studies, yet for most sites the
function is not known. Some phosphorylation sites are located in known
substrate motifs for kinases upstream of Akt. For example, Ser129 in Akt1 is
phosphorylated by casein kinase 2 (CK2), which increases Akt catalytic activity
and promotes cell survival (59).
Other types of post-translational modifications are also involved in Akt
regulation such as acetylation, ubiquitination, sumoylation and glycosylation
(60). Acetylation of Akt is associated with reduced levels of phosphorylation and
Akt activity. The acetyltransferase p300 is involved in Akt acetylation while
sirtuin 1 (SIRT1) deacetylates Akt, promoting localization with PIP3 (61).
Ubiquitination at Lys48 degrades Akt and abolishes Akt signaling (62). It is
thought that sumoylation is an important modification for Akt activation (60), yet
the exact mechanism of action is not known; the enzyme can be highly activated
in the absence of SUMO (14). Finally, glycosylation of Thr308 inhibits Akt
activation (63).
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1.5 Akt activity drives cell growth and survival programs
Akt blocks pro-apoptotic proteins to promote cell survival. Key substrates
regulated by Akt1-dependent phosphorylation include B cell lymphoma-2 (Bcl-2)
homology domain 3 protein (BAD), the FOXO family of transcription factors, as
well as p53 and the p53 regulating E3 ubiquitin ligase MDM2 (5).
Akt1-dependent

phosphorylation

impacts

target

proteins

through

multiple mechanisms. For example, Akt1 phosphorylates BAD at Ser136. Once
phosphorylated, phospho-BAD binds to the regulatory protein 14-3-3 which
prevents heterodimerization with BCL-2 and BCL-xl.
BAD initiates cell death (64).

Heterodimerization of
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S473D

ATP¢

pT308

GSK3b
peptide

Figure 1.3. Structure of human Akt1. The two activation sites, Thr308 and
Ser473; several additional phosphorylation sites (yellow highlight), GSK-3β
peptide in complex with the kinase domain (purple) of Akt1 and a nonhydrolyzable ATP analog (ATP’ = AMP-PNP) are shown. Structural data were
obtained from PDB codes: 3CQU (65), 1O6K (18).

GSK-3 isoforms were the first identified substrates of Akt1 (66).
GSK-3 was initially identified as a key regulator in glycogen synthesis (67). Later
it was discovered that GSK-3 regulates a plethora of cellular substrates involved
in metabolism, signaling and structural functions. Akt targets include glycogen
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synthase, β-catenin, cyclic-AMP response element binding (CREB) protein,
insulin receptor substrate 1 (IRS1) and many others (68).
The prototypical Akt substrate, GSK-3 is a key mediator of both insulin
signaling and Wnt signaling pathways (6,69). Akt1 inactivates GSK-3 by
phosphorylating the N-terminal residues Ser21 in GSK3α and Ser9 in GSK3β,
respectively (66). Inhibition of GSK3 activates glycogen synthase and converts
glucose into glycogen. Inhibition of GSK-3 further promotes protein synthesis by
activating the elongation factor 2B (eEF2B) (70).
A similar regulatory mechanism is associated with Akt1-depedent
phosphorylation of the FOXO subfamily of fork head transcription factors, which
includes FOXO1, FOXO3 and FOXO4. These transcription factors reside in the
nucleus in growth factor deprived cells. The function of FOXO transcription
factors varies depending on the cell type. In general, these factors promote
expression of genes associated with cell differentiation, apoptosis, proliferation,
and DNA damage (71). Once the cells are stimulated with growth factors and Akt
is activated, Akt phosphorylates FOXO3 at phosphorylation sites Thr32, Ser253,
and Ser315 (38). Phosphorylated FOXO3 is bound to 14-3-3, which displaces these
transcription factors from their target apoptotic genes and facilitates their
shuttling to the cytosol (38,72). Akt also acts on other FOXO members by a
similar mechanism (reviewed in (73)).
Another target of Akt1 is the E3 ubiquitin ligase, MDM2, that negatively
regulates the activity of the tumor suppressor protein and transcription factor
p53 (74). MDM2 polyubiquitinates p53 and directs p53 for proteasomal
degradation by enabling the association of p53 with p300, which is an E4
ubiquitin ligase. Activation of p53 by cellular responses including DNA damage,
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promote cell cycle arrest and apoptosis (75,76). Akt promotes cell survival in part
by counteracting p53-dependent apoptosis. Akt phosphorylates MDM2 at two
sites, Ser166 and Ser186. Phosphorylated MDM2 translocate to the nucleus where
it triggers p53 ubiquitination and degradation (5).
The mTORC1 protein complex acts as a central regulatory body in protein
synthesis and cell growth. Akt phosphorylates tuberous sclerosis factor 2 (TSC2),
a negative regulator of mTORC1 (77). Furthermore, Akt phosphorylates the
PRAS40 subunit of mTORC1. PRAS40 is also a negative regulator of mTORC1
and Akt1 phosphorylation stabilizes mTORC1 activity by relieving the inhibitory
effect of the PRAS40 domain (78). Through inactivation mechanisms of TSC2 and
PRAS40 by Akt, mTORC1 activity is stabilized to promote protein synthesis and
cell growth (77,78).

1.6 Hyper-activation of Akt in cancer
The significance of Akt activation in cancer has been a widely studied due
to the prominent role of Akt1 in stimulating cell growth and survival pathways
(79,80). Hyper-phosphorylated and hyper-active Akt1 is known to facilitate
cancer cell survival creating a chemo-resistant environment (81). Due to these
reasons Akt1 hyper-activation is considered as a hallmark of cancers, including
breast (56), lung (82,83), and head and neck (84). Certain somatic mutations also
cause Akt mediated carcinogenesis. Glu17Lys mutation at the PH domain
promotes Akt1 binding to plasma membrane, which constitutively activates Akt1
(16). The other Akt isozymes are also hyperactive in certain cancers (1,79,85).
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The phosphorylation status of Akt1 at positions Ser473 and Thr308 are
used as diagnostic markers for multiple cancers (82,83,86). Higher levels of
Thr308 and Ser473 phosphorylation is correlated with poor clinical outcome with
patients with head and neck squamous cell carcinoma

(84,87). Ser473

phosphorylation is the most commonly used biomarker for hyper-active Akt1
(82,88). Thr308 phosphorylation is also as a prognostic biomarker in non-small
cell lung cancer (83) and acute myeloid leukemia (86).
Different cancer types are associated with isozyme specific Akt activity.
Akt1 promotes cell proliferation in breast cancers (89), Akt2 highly active in
hepatocellular carcinoma (90) and colorectal cancers (85) and Akt3 is hyper-active
in estrogen receptor negative breast tumors and melanoma (80).
A somatic mutation; Glu17Lys in Akt1 was identified in breast cancers
(91). This mutation is present in the PH domain and helps in constitutive
membrane localization of Akt1 (91). Yet, there is no evidence of a similar PH
domain mutation in Akt2 (80). A later study revealed the presence of Glu17Lys in
Akt3 in two melanomas of one patient (92).
Since more than 50% of human tumors are characterized by hyper-active
Akt, numerous studies have been conducted to develop Akt specific anticancer
drugs (6). After successful in vitro, cell and animal model testing, small molecule
inhibitors for Akt have been introduced to clinical trials. However, most of them
failed in clinical trials. Inefficiencies during patient stratification, activation of the
negative feed-back loops while Akt is inhibited (93), function of other PI3K
effectors such as serum and glucocorticoid-induced protein kinase isoforms that
activate downstream targets of PI3K/Akt pathway (94) are among the challenges
for future work and in the development of clinically successful Akt inhibitors.
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1.7 Investigating Akt phosphorylation in vitro and in cells
Amino acid substitutions are often used as a genetic tool to mimic the
function of protein modifications. In studies of protein kinases there are multiple
challenges that exist to producing proteins with site-specific phosphorylation(s).
It

is

challenging

to

characterize

the

functionality

of

an

individual

phosphorylation site since a functional protein may require more than one
phosphorylation for activity. For >90% of human phosphorylation sites, the
upstream kinases for the site is not known (95). Even when upstream kinases are
known, they often must be activated themselves by phosphorylation and many
kinases phosphorylate at multiple sites in one protein, thus, hampering our
ability to generate protein with programmed phosphorylation.
As a resolution to this problem, acidic amino acids like glutamate (Glu) or
aspartate (Asp) are used to mimic phosphorylation. Though a phosphate adds
two negative charges to the modified protein, the closest resemblance for this to
be selected from the canonical amino acid pool are the acidic residues Glu or
Asp. Ala mutations are used to mimic non-phosphorylation. Although mimics
may be interesting mutants, they are unable to mimic true phosphorylation
sometimes.
Thr308Asp

mutant

of

Akt1

expressed

and

purified

as

an

immunoprecipitate in serum starved COS-1 cell line was 5-fold more active than
the wild type Akt (55). When MAPKAP-kinase 2 activated this mutant in vitro, it
was 5-fold more active relative to the activated wild type Akt1 in an in vitro
kinase assay. The authors conclude that the Asp308 is a suitable mutation for
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mimicking phosphorylation (55). However, when the same construct was used to
express Thr308Asp mutant in HEK293 cells, the enzyme was totally inactive
according to an independent group of investigators (15). Further studies revealed
that Asp308 mutant did not show transforming ability in contrast to the truly
phosphorylated Akt in chicken embryonic fibroblasts (96). Akt studies often use
these

mimics

to

characterize

Akt

functionality

(41,58),

however,

the

preponderance of direct evidence suggests that in Akt1, acidic amino acids fail to
mimic phosphorylation (96).
To overcome the drawbacks listed above, novel synthetic biology
approaches enable expansion of the genetic code with phosphoserine (97).
Genetic code expansion refers to the ability to reassign codons, normally a stop
codon, to include additional or unnatural amino acids beyond the canonical 20.
These systems often require a tRNA and aminoacyl-tRNA synthetase pair that is
orthogonal to the host expression system (98,99), which means the tRNA and
synthetase enzyme pair should not cross react with the host tRNAs and tRNA
synthatase enzymes. In these systems the unnatural or modified amino acids are
incorporated into proteins during translation. Genetic code expansion is used to
synthesize phosphoproteins in Escherichia coli with site-specifically introduced
phosphoserine residues. George et al. (2016) have site specifically incorporated
phosphoserine into ubiquitin (100). An active form of human mitogen-activated
ERK activating kinase 1 (MEK1) was the first kinase to be produced by sitespecific incorporation of phosphoserine (97). Recent studies have reported sitespecific incorporation of phosphotyrosine and phosphothreonine following
related methodologies (101,102). Incorporation of phosphotyrosine has confirmed
by electron spray ionization mass spec (ESI-MS) analysis using Xenopus
calmodulin and green fluorescent protein (GFP) (101). The yields of calmodulin
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and GFP were 1.0 mg/L and 1.5 mg/L, respectively. Incorporation of
phosphotyrosine

produced

a

mixture

of

phosphorylated

and

non-

phosphorylated tyrosines. Removal of a phosphatase gene (ycdX) enabled
production of a homogeneous mixture of phosphothreonine-incorporated
ubiquitin (102).
Co-expression of upstream kinases to phosphorylate its target substrates is
another feasible method used to characterize the functionality of phosphorylation
sites. This method has already being used to phosphorylate Thr308 of Akt1 by coexpressing upstream kinase PDK1 in E. coli (15).
Another method is the in vitro phosphorylation of target substrates. In this
method the upstream kinases along with ATP are incubated to facilitate
phosphorylation. However, in kinases like Akt there exist special cellular
requirements like the presence of lipid second messengers and phosphorylation
of multiple upstream kinases to facilitate phosphorylation of Akt1, limiting the
yield of phospho-protein and the usefulness of this approach for Akt1 (103).

1.8 Scope of the thesis
Since Akt1 is a proto-oncogene, its activation mechanisms and therapeutic
interventions have been studied extensively (5). However, apart from the known
contribution to activation, the specific role of each activation site, i.e., Thr308 and
Ser473, on Akt1 activity are not known. Because the phosphorylation of each
activation site is used as a biomarker for different types of cancers, the relevance
of Akt1 phosphorylation status to disease is well documented (82-84). The
inability to produce site specifically phosphorylated Akt variants have created a
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barrier in unraveling the undiscovered and unique functionality of the two
activation sites.
As discussed in Section 1.7, since the methods used in recent studies (i.e.
phosphomimetics, Ala mutations, partially active Akt produced in eukaryotic
cells) are not the best suited candidates for this purpose, I developed a facile
strategy to produce site-specifically and quantitatively phosphorylated Akt1
variants in E. coli. I used a combined approach of using genetic code expansion
strategy with upstream kinase expression to produce doubly phosphorylated
Akt1. Expression of these systems individually enabled production of singly
phosphorylated Akt1 variants.
In chapter 2, I quantified how each phosphorylation site contributes to the
overall activation of Akt1. We have used in vitro assays, mass spectrometry and,
in collaboration with Alexandra Newton (UCSD) live cell imaging techniques to
discover the unique role of each phosphorylation site on the activation of Akt1 in
vitro and in mammalian cells (19).
Chapter 3 focuses on the impact of each phosphorylation site on the autoand chemical inhibition of Akt1. Deletion of PH domain to release the autoinhibitory effect increased the enzyme activity for all three phosphorylated Akt1
variants. Phosphorylation of Ser473 showed resistance to chemical inhibition by
the clinically relevant inhibitor Akti1/2.
The exact mechanism of Akt’s substrate selection is still under
investigation. In chapter 4, I determined how the phosphorylation status of Akt1
modulates substrate selectivity. I used peptides derived from all known
substrates of Akt1, alanine mutagenic scans, and oriented peptide array library
screens to systematically reveal the ability of Akt1 phosphorylation status to
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globally regulate substrate selectivity. The data revealed that each phospho-form
of Akt1 has distinct substrate requirements and Ser473 plays a key role in
modulating global substrate selectivity.
Using genetic code expansion and upstream kinase phosphorylation, I was
able to produce site specifically phosphorylated Akt1 variants which act as
indispensable tools in characterizing the functionality of each activation site of
Akt1. This is the first time that genetic code expansion has been used to produce
Akt1 carrying single phosphorylation at Ser473. Further we have shown that
upstream kinase expression is a compatible mode of phosphorylation with
genetic code expansion. This novel methodological advancement could be
employed with other cellular proteins, especially with kinases, to generate site
specifically phosphorylated protein variants that will help to overcome the
existing limitations on characterizing the unique functionality of specific
phosphorylation sites.
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Chapter 2

2 Genetic code expansion and live cell imaging reveal that
Thr308 phosphorylation is irreplaceable and sufficient for
Akt1 activity

2.1 Abstract
The proto-oncogene Akt/protein kinase B (PKB) is a pivotal signal transducer
for growth and survival. Growth factor stimulation leads to Akt phosphorylation
at two regulatory sites (Thr308, Ser473), acutely activating Akt signaling.
Delineating the exact role of each regulatory site is, however, technically
challenging and has remained elusive. Here, we used genetic code expansion to
produce site-specifically phosphorylated Akt1 in order to dissect the contribution
of each regulatory site to Akt1 activity. We achieved recombinant production of
full length Akt1 containing site-specific pThr and pSer residues for the first time.
Our analysis of Akt1 site-specifically phosphorylated at either or both sites
revealed that phosphorylation at both sites increases the apparent catalytic rate
1500-fold relative to un-phosphorylated Akt1, an increase attributable primarily
to phosphorylation

at

Thr308. Live

imaging of

COS7

cells

confirmed

that phosphorylation of Thr308, but not Ser473, is required for cellular activation
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of Akt. We found in vitro and in the cell that pThr308 function cannot be
mimicked with acidic residues nor could un-phosphorylated Thr308 be
mimicked by an Ala mutation. An Akt1 variant with pSer308 achieved only
partial

enzymatic

and cellular

signaling

activity,

revealing

a

critical

interaction between the γ-methyl group of pThr308 and Cys310 in the Akt1 active
site. Thus, pThr308 is necessary and sufficient to stimulate Akt signaling in cells
and the common use of phosphomimetics is not appropriate for studying the
biology of Akt signaling. Our data also indicate that pThr308 should be regarded
as the primary diagnostic marker of Akt activity.

2.2 Introduction
The proto-oncogene Akt/protein kinase B (PKB) is a central transducer of
growth and survival signaling (1). There are three isozymes of Akt in mammals.
Akt1, Akt2, and Akt3 include kinase domains with extensive homology to those
of protein kinases A, G and C, defining them as members of the AGC family of
Ser/Thr protein kinases (2). Akt transduces signals in the phosphoinositide 3kinase (PI3K) signaling cascade, which is one of the most commonly deregulated
pathways in human cancer (3,4). Thus, enormous efforts are directed at
understanding the mechanisms of activation of Akt and how to target these
enzymes therapeutically (5).
Akt activity in the cell is acutely controlled by growth factor-dependent
phosphorylation mechanisms (6). Following activation by agonist-bound
receptor tyrosine kinases at the plasma membrane, PI3K phosphorylates
phosphatidylinositol-4, 5-bisphosphate (PIP2) to generate the lipid second
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messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) (7). This second
messenger engages Akt at the plasma membrane by binding its autoinhibitory
pleckstrin homology (PH) domain, resulting in a conformational change that
exposes the kinase domain for phosphorylation (8). The phosphoinositide
dependent kinase 1 (PDK-1) phosphorylates a conserved Thr on the activation
loop (Thr308 in Akt1), leading to partial activation of Akt (9). Full activation of
Akt1 results from a second phosphorylation event in the C-terminal tail, a
regulatory region referred to as the ‘hydrophobic motif’ (Ser473 in Akt1) that was
originally identified in protein kinase C and S6 kinase (10-12). Phosphorylation at
Ser473 in Akt1 depends on the mammalian target of rapamycin complex 2
(mTORC2) (13). In addition, Akt is co-translationally and constitutively
phosphorylated at another C-terminal site termed the ‘turn motif’ (Thr450 in
Akt1) by mTORC2, a modification that regulates the stability of the enzyme (14).
Given that Akt is activated by phosphorylation of Thr308 and Ser473, phosphospecific antibodies to these sites are widely used as diagnostic markers (15-17).
To a striking degree, many clinical (18-21) and biochemical (22) studies rely solely
on Ser473 phosphorylation as a proxy for Akt activity.
The activation of Akt by phosphorylation is well established (8), yet the
contribution of each specific phosphorylation site towards the maximal Akt
activity and pathogenesis is less well defined. This knowledge gap resulted from
the

inability

previously

to

prepare

Akt

variants

in

site-specifically

phosphorylated forms. Earlier work established production of partially active
and truncated Akt1 in E. coli. The attempt was unsuccessful in producing a
sufficient amount of full length Akt1 to determine activity (23). Instead this study
relied on a construct lacking the PH domain with Ser473 substituted by
glutamate, and the authors were unable to show how the phosphomimetic
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compared to pSer at position 473 (23). A protocol for active Akt1 production in
insect (Sf9) cells has been established (24). The ability to generate ppAkt1
required a complex and low yield in vitro procedure to phosphorylate Akt with 2
additional purified upstream kinases in the presence of lipid vesicles (24). Protein
production in Sf9 cells fails to produce Akt1 with site-specific or programmed
phosphorylation. The resulting protein is a mixture of singly and doubly
phosphorylated species (25) and includes phosphorylation at Thr450 in addition
to potentially other modifications, so the ability to isolate the activity of each
regulatory site individually and in precise combinations has remained elusive. As
demonstrated below, we have developed a facile and efficient approach that is a
novel combination of in vivo enzymatic phosphorylation with genetic code
expansion to produce pAkt1 and ppAkt1 variants with specifically programmed
phosphorylation (Figure 2.1).
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Figure 2.1 A novel route to doubly phosphorylated and active Akt1. (A)
Schematic representation of recombinant Akt1 biosynthesis with pSer473
genetically encoded in response to the UAG codon and pThr308 enzymatically
phosphorylated in vivo in E. coli. Genetically encoded pSer incorporation requires
phosphoseryl-tRNA synthetase (SepRS), a UAG-decoding tRNASep, and the
elongation factor mutant (EFSep). (B) Enzyme activity of differentially
phosphorylated Akt1 variants with a GSK-3β substrate peptide. Akt1
quantitatively phosphorylated at both 308 and 473 (ppAktS473, T308, blue diamonds)
showed maximal activity compared to the un-phosphorylated Akt1 (gray circles),
and singly phosphorylated Akt1 variants: pAktT308 (black cross) and pAktS473
(brown diamonds). The reported values represent the mean of triplicate
experiments with error bars indicating 1 standard deviation. Lower activity
variants show above background kinase activity (inset).
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Because of the previous technological barriers to producing specifically
phosphorylated kinase variants, a significant literature continues to accumulate
for Akt (23,26-32) and other kinases (33), in which ‘phosphomimetic’
substitutions are used as a genetic tool to interrogate the biological consequences
of phosphate on a site of interest (33). The rationale behind these experiments is
that the acidic residues, Asp and Glu, are negatively charged like phosphate. Yet
the carboxylate of an acidic amino acid has considerably less electronegativity
than a phosphate and a significantly smaller hydration sphere and volume
(34,35). A complementary approach involves nullifying the effect of a particular
phosphorylation site by introducing a non-phosphorylatable Ala mutation (26);
however, an Ala is considerably smaller and less polar than a Ser or Thr, and Ala
lacks the capacity to form hydrogen bonds. In light of these observations, the
widespread use of Ala and phosphomimetic mutants in signaling studies begs
the question of how appropriate these mutations are to interrogate the cellular
function of Akt or other phosphorylated proteins.
Here we provide, for the first time, a quantitative analysis of the contribution
of phosphate at positions 308 and 473 in the catalytic activity of Akt1 and,
additionally, examine the effects of substitutions of acidic residues or Ala at these
positions. To do this, we developed an optimal strategy to produce recombinant
full-length

human

Akt1

in

Escherichia

coli

with

genetically

encoded

phosphoserine (pSer) introduced at specific phosphorylation sites. We measured
the activity of singly and doubly phosphorylated Akt1 variants with phosphate
at positions 308 (pAkt1S308, pAkt1T308) and/or 473 (pAkt1S473) in comparison to
inactive and un-phosphorylated Akt1 as well as Akt1 variants with
phosphomimetic Glu or Asp mutations. With a Förster resonance energy transfer
(FRET)-based Akt activity sensor (BKAR) (36), we conducted complementary

35
experiments of specific Akt1 variants in live cells. Our data reveal that, in
comparison to un-phosphorylated enzyme, phosphorylation of Thr308 alone
increases the apparent catalytic rate by nearly 400-fold, which is sufficient to
observe maximal signaling in cells. Phosphorylation of only Ser473 boosts Akt1
activity by ~80-fold over un-phosphorylated enzyme, however, our data suggest
that phosphorylation at Ser473 alone may not be sufficient to elicit Akt1 signaling
in cells. Thus, phosphorylation of Thr308 is necessary and sufficient for the
activity of Akt. Importantly, our cell based observations and biochemical data
confirm that Ala does not mimic a non-phosphorylated Thr308 and further that
acidic residues fail to activate Akt1. Phosphomimetic substitutions, therefore, do
not mimic phosphorylation in Akt1 at either of its two key regulatory
phosphorylation sites.

2.3 Materials and methods

2.3.1 Bacterial strains and plasmids. The full length human AKT1 gene was
cloned into a pUC18-derived vector (pDS1(38)) and pCDFDuet1 vector (see SI
methods). Ser473 and Thr308 sites were mutated by site-directed mutagenesis in
E. coli DH5α to amber (TAG), Asp (GAC), or Glu (GAG) codons according to
previously described methods (65). All clones were verified by DNA sequencing
(London Genomics Research Center, Robarts Research Institute, London;
Genewiz Inc. NJ, USA). Phosphoproteins were produced by genetically encoding
pSer at UAG codons with the 2nd generation pSer incorporation system (pDSpSer2, kanamycin resistant) (38,66). Recombinant Akt1 and pAkt1 variants were
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over expressed in E. coli BL21(DE3) (Invitrogen, California, USA); exogenous
pSer (5 mM) was added to the expression media for production of pAkt1 variants
(see SI methods for a detailed protocol). For the imaging studies, the mouse AKT1
gene (a gift from A. Toker; 98.3% amino acid identity to human Akt1) was
subcloned into pcDNA3 (Invitrogen) containing mCherry at its amino-terminus.
Mutations were generated by QuikChange mutagenesis (Agilent Genomics) and
confirmed by Sanger sequencing (Eton Bioscience). Generation of BKAR was
previously described (36).

2.3.2 Protein production and purification. For phosphoprotein production,
pDS1-Akt1 expression plasmid variants with TAG codons at the indicated
phospho-site were co-transformed with pDS-pSer2 into E. coli BL21(DE3). For
unphosphorylated and phosphomimetic Akt1 variants, the appropriate pDS1Akt1 plasmid was transformed alone into BL21 (DE3). Cells were grown and
pelleted at 5000 × g as described in SI methods. The cell pellets were resuspended in lysis buffer (20 mM Hepes, 150 mM NaCl, 3 mM βmercaptoethanol, 3mM Dithiothreitol (DTT), 10 mM Imidazole) at 10 ml per
gram of cells. Lysis buffer for phosphoproteins contained phosphatase inhibitors
(1 mM Na3VO4 and 5 mM NaF). One tablet of ethylenediaminetetraacetic acid
(EDTA)-free mini protease inhibitor cocktail (Roche, Mississauga, ON, Canada)
and 1 mM phenylmethylsulfonyl fluoride (PMSF) were added to the cell
suspension (typically 200 ml). Cells were treated with lysozyme (1 mg/ml) for 20
min, shaking at 4°C and lysed using French Pressure Cell Press (American
Instrument Co. Inc. Maryland, USA) at 1000 psi. Cell lysates were centrifuged at
38,000 × g for 1 h at 4°C. The supernatant was filtered through a 1.2 µm filter,
mixed with Ni-NTA affinity beads (Thermo Scientific) and pre-equilibrated with
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lysis buffer for 1 h. Finally, proteins bound to beads were purified under gravity
flow. Elution fractions were further purified using Superdex200 gel filtration
column attached to an AKTA Pure L1 fast protein liquid chromatography (FPLC)
system (GE Healthcare, Little Chalfont, UK) (see SI Methods). Protein yields
ranged from 20-100 µg/l E. coli culture.

2.3.3 In vitro Akt1 kinase assay. For the kinase activity assay, we established a
set of common conditions to assay a series of Akt1 variants of widely varying
activity. To achieve this, we worked in a regime of sub-saturating ATP, thus, our
apparent reaction constants (kapp) serve well to compare the Akt1 variants to one
another, but these rates are significantly lower than kcat. Our data represent single
turnover kinetics. Akt1 activity was determined using 200 µM substrate peptide
CKRPRAASFAE (SignalChem, Vancouver, BC, Canada) derived from the natural
Akt1 substrate, glycogen synthase kinase (GSK-3β). The reported KM of Akt1 for a
similar substrate peptide is 18 µM (67), so the peptide concentration is in excess.
Assays were performed in 3-(N-morpholino)propanesulfonic acid (MOPS, 25
mM, pH 7.0), β-glycerolphosphate (12.5 mM), MgCl2 (25 mM), ethylene glycolbis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA, 5 mM, pH 8.0), EDTA
(2 mM), ATP (20 µM) and 0.4 µCi (33 nM) γ-[32P]-ATP in a 30 µl reaction volume,
at 37°C in 30 min time courses. Unless otherwise indicated, reactions were
initiated by the addition of 18 pmol of the indicated Akt1 variant (to yield a
concentration of 600 nM) and quenched by spotting 5 µl from each reaction on
P81 paper at specified time points (68). Following washes with 1% phosphoric
acid (3 × 10 min) and 95% ethanol (1 × 5 min), P81 paper was air-dried and
exposed to a phosphor screen. The
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P-peptide products were imaged and
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quantitated using a Storm 860 Molecular Imager and ImageQuant TL software
(Molecular Dynamics, Caesarea, Israel).

2.3.4 Cell culture media and conditions. COS-7 cells were maintained in DMEM
(Cellgro) containing 10% fetal bovine serum and 1% penicillin/streptomycin at
37°C in 5% CO2. For cell imaging experiments, cells were plated onto sterilized
glass coverslips in 35-mm dishes prior to transfection with 1 µg pcDNA3-BKAR
with or without 1 µg pcDNA3-mCherry-Akt using Lipofectamine 3000
(Invitrogen). For experiments in which low expression levels of Cherry-Akt were
desired, cells were transfected with 1 µg pcDNA3-BKAR and 0.05 µg pcDNA3mCherry-Akt. Cells were imaged within 24 hours following transfection. For
Western blot experiments, in which average overexpressed Akt levels were
desired to be at a similar level to endogenous Akt, COS-7 cells were transfected
with 0.05 µg pcDNA3-mCherry-Akt using Lipofectamine 3000 (Invitrogen) in 6well dishes.

2.3.5 Cell imaging. Transfected COS-7 cells were serum-starved at least 4 hours
(as long as overnight) prior to imaging. Cells were washed one time in Hank’s
Balanced Salt Solution (HBSS, Cellgro) supplemented with 1 mM CaCl2 and
imaged in this HBSS in the dark at room temperature. Data were collected on a
Zeiss Axiovert microscope (Carl Zeiss Microimaging, Inc) using a MicroMax
digital camera (Roper-Princeton Instruments) controlled by MetaFluor software
(Universal Imaging, Corp.). Optical filters were obtained from Chroma
Technologies and Semrock. Data were collected through a 10% neutral density
filter. Cyan fluorescent protein (CFP) and FRET images were obtained every 15
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seconds through a 420/20 nm excitation filter, a 450 nm dichroic mirror and a
475/40 nm or 535/25 emission filter for CFP and FRET, respectively. Cherry
images were acquired through a 560/25 excitation filter, a 593 nm dichroic mirror
and a 629/53 emission filter. Excitation and emission filters were switched in filter
wheels (Lambda 10-2, Sutter). Integration times were 200 ms for CFP and FRET
and 150 ms for mCherry. Cells were stimulated with 50 ng/ml EGF (PeproTech,
Inc.) and then treated with 20 µM GDC 0068 (Selleckchem.com) at the indicated
times. Data were normalized to the first 3 minutes of the experiment for each cell.
Error bars represent 1 standard error of the mean.

2.3.6 Western Blotting. Within 24 hours after COS-7 cell transfection, cells were
serum-starved for at least 4 hours. Cells were rinsed once in HBSS/1 mM Ca2+ and
then left untreated or stimulated with 50 ng/ml EGF for 10 minutes at room
temperature. Cells were lysed in 50 mM Na2HPO4, 1 mM Na4P2O7, 20 mM NaF,
2 mM EDTA, 2 mM EGTA, 1% Triton X-100 (supplemented with 1 mM DTT,
200 µM benzamidine, 40 µg/ml leupeptin, 300 µM phenylmethylsulfonyl fluoride,
and 1 µM microcystin) and cleared by a high-speed centrifugation for 2.5 min.
The cleared lysates were analyzed by Western blotting to determine the relative
amounts of Akt-Thr308 (Phospho-Akt (Thr308), Cell Signaling #9275) or AktSer473 (Phospho-Akt (Ser473)(D9E) XP, Cell Signaling #4060) phosphorylation.
Total Akt levels were assessed with an antibody against all Akt isozymes (AntiAKT1/2/3,

Abcam

chemiluminescence.

#126811).

Western

blots

were

developed

using
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2.4 Results
2.4.1 Activation of full-length pAkt1 variants by genetic code expansion. We
used in vitro radioactive kinase assays with γ-[32P]-ATP to test the activity of full
length Akt1 variants that were made with site-specifically incorporated pSer
residues (Figure S2.1, S2.2, S2.33). The assays quantify the ability of each Akt1
variant to phosphorylate an Akt1 substrate peptide (CKRPRAASFAE) that is
derived from the natural Akt1 target glycogen synthase kinase 3β (GSK-3β).
Using genetic code expansion (37,38), we reassigned the UAG stop codon to
genetically encode pSer in recombinant Akt1 proteins produced in E. coli. For
example, we expressed pAkt1S473 with a genetically-encoded pSer residue
inserted in response to a UAG codon at position 473 in the Akt1 construct. We
used Multiple Reaction Monitoring Tandem Mass Spectrometry (MRM-MS/MS)
to unambiguously identify pSer at position 473 (Figure S2.3). Geneticallyencoded pAkt1S473 showed a clear signal for phosphorylation at position 473 with
no evidence of de-phosphorylation (Figure S2.3A,B). In wild type or unphosphorylated Akt1, Ser473 is readily detected with no evidence of pSer473
(Figure S2.3C,D).
For

pThr

incorporation

phosphorylation

by

the

at

position

upstream

308,

kinase

we

relied

on

enzymatic

PDK1

(23).

We

produced

phosphorylated pAkt1T308 as well as the doubly-phosphorylated ppAkt1T308,S473 by
co-expressing PDK1 in E. coli with either the wild-type Akt1 or pAkt1S473
constructs, respectively (Figure 2.1A). We confirmed phosphorylation at Thr308
(Figure S2.4) by Parallel Reaction Monitoring Tandem Mass Spectrometry (PRMMS/MS). The MS/MS data identified an insignificant level of Thr308 in the
pAkt1T308 sample, indicating essentially quantitative phosphorylation of Thr308
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by PDK1 in E. coli. Finally, we confirmed site-specific phosphorylation of the
ppAkt1T308,S473 variant using PRM-MS/MS (Figure S2.2). In the MS/MS analysis, we
achieved up to 90% coverage of the full length Akt1 (Figure S2.2D), and we were
unable to identify significant peptides with modifications other than the
anticipated and programmed phosphorylations. The data indicate that both
genetic code expansion and PDK1 phosphorylation are highly site-specific, and
that endogenous modification or de-phosphorylation by E. coli enzymes is absent
or minimal.
We first measured the activity of Akt phosphorylated at both positions
(ppAkt1T308/S473). Doubly phosphorylated Akt1 (Figure S2.4) had an apparent
reaction rate of 44 ± 6 fmol/min/pmol of enzyme (Figure 2.1, Table 2.1, Figure S2.5,
S2.6). We performed these kinase assays in conditions of sub-saturating ATP. We
chose these conditions so that Akt1 protein variants with a wide range of
activities could be assayed using the same experimental conditions. In order to
compare the relative activities of Akt1 and pAkt1 variants, we determined an
apparent catalytic rate (kapp = vo/[Akt1]) based on the initial velocity (vo) observed
in the kinase assays. Under sub-saturating ATP, our reaction velocities are far
below Vmax for Akt and related kinases (24,39); kapp is not intended to estimate kcat.
Interestingly, the bacterially expressed ppAkt1 construct consistently migrated
slightly faster than the other pAkt1 variants and Akt1 mutants on sodium
dodecyl sulphate (SDS)-PAGE (Figure S2.1, Figure S2.2A). We determined that
this was not a result of premature termination of the translation product because
PRM-MS/MS

unambiguously

phosphorylated ppAktT308,

S473

identified

intact

full

length

and

doubly

(Figure S2.2B-D). We found no evidence of

truncation or stopping at the UAG473 codon, or de-phosphorylation according to
mass spectrometry. Phosphorylation at Thr450 is known to specifically decrease
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the electrophoretic mobility of Akt1 expressed in mammalian cells (40). Our
bacterially expressed pAkt1 variants show no evidence of phosphorylation at
Thr450. These observations together suggest that phosphorylation status impacts
the mobility of Akt1 on SDS-PAGE.
Akt1 variants that contain pThr308 were so highly active under the conditions
of our assays that we reduced the Akt1 concentration 10-fold in order to establish
a linear range of activity to determine vo (Figure S2.5). Un-phosphorylated Akt1
was essentially inactive, showing a low basal activity of 0.03 ± 0.01
fmol/min/pmol of enzyme (Table 2.1). Thus, in comparison to un-phosphorylated
enzyme, phosphorylation at both activating sites increased the catalytic rate of
Akt1 by 1500-fold. We note this is the first time that the activity of Akt1 has been
definitively measured and reported for homogenously pure variants with sitespecifically programmed phosphorylation at both key regulatory sites and
without phosphate occupancy at other sites (e.g., pThr450).
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Table 2.1 Specific activity of Akt1 variants

Akt1 variant
Akt1 (unphosphorylated)

Akt1
Initial
Apparent catalytic rate, Activation
amount velocity (vo)
kapp
(fold increase)
(pmol) (fmol/min) (fmol/min/pmol Akt1)
18

0.6 ± 0.2

0.03 ± 0.01

1

18
6
1.8

46 ± 5
2.9 ± 0.2
22 ± 4

2.5 ± 0.3
0.48 ± 0.03
12 ± 2

83
16
400

ppAkt1 (pT308, pS473)*

1.8

79 ± 11

44 ± 6

1467

Phosphomimetics
E473
E308
D473
D308

18
18
18
18

1.5 ± 0.1
1.0 ± 0.1
0.40 ± 0.03
2.6 ± 0.1

0.083 ± 0.006
0.056 ± 0.006
0.022 ± 0.002
0.14 ± 0.01

2.7
1.9
0.7
5

pAkt1S473 mutants
D308
A308

18
18

83 ± 1
5.4 ± 0.3

4.6 ± 0.1
0.30 ± 0.02

153
10

pAkt1T308 mutants
D473
E473
A473

18
18
18

188 ± 11
120 ± 16
74 ± 3

10.4 ± 0.6
6.6 ± 0.8
4.1 ± 0.2

348
222
137

pAkt1
pS473
pS308
pT308*

Initial velocities (v0) and apparent catalytic rates (v0/[Akt1]) of each enzyme
variant were calculated using linear regression analysis of the activity plots.
*In order to measure the initial velocity accurately, the most active variants were
assayed at a 10-fold reduced enzyme concentration (Figure S2.5).
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2.4.2 Phosphorylation of Thr308 is necessary and sufficient for Akt1 activation.
We next examined the contribution of phosphate at each site individually to the
maximal activity of Akt1. Based on measurements of the initial velocity, the
activity of mono-phosphorylated pAkt1T308 corresponded to ~27% that of the
doubly-phosphorylated species (Figure 2.1, Table 2.1). Thus, phosphorylation at
the PDK-1 site alone results in an over 400-fold increase in activity compared to
the un-phosphorylated enzyme. These data establish that phosphorylation at
Thr308 alone is sufficient for robust activation of Akt. Purified, monophosphorylated pAkt1S473 was considerably less active than protein with
phosphate at Thr308 (Figure 2.1). pAkt1S473 had activity that corresponded to
about 5% of the activity of the doubly-phosphorylated species (Table 2.1).
Although significantly reduced relative to that of the doubly-phosphorylated
species, activity from pAkt1S473 still represents an 80-fold increase over the unphosphorylated Akt1 enzyme. Thus, genetic code expansion with pSer enables
production of active Akt1 without the need to purify and activate upstream Akt1
kinases (24). In the absence of substrate peptide, we were able to detect low, but
above

background,

phosphorylation

phosphorylation by pAkt1S473 (Figure 2.2).

that

may

be

attributed

to

auto-
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Figure 2.2 Activity of singly phosphorylated Akt1 variants with regulatory site
mutations. (A) Akt1 enzyme activity is shown for variants with S473
phosphorylated and T308 un-phosphorylated (brown diamond), or mutated:
T308D

(purple

triangles),

T308A

(orange

squares).

Controls

include

unphosphorylated Akt1 (gray circles), and pAkt1S473 in the absence of substrate
peptide (-peptide, green crosses). (B) In comparison to pAkt1T308 activity (black
crosses) and in the context of Akt1 phosphorylated at T308, mutations S473D
(blue triangles), S473E (magenta crosses) or S473A (cyan squares) resulted in
marginally reduced activity. All reported values represent the mean of triplicate
experiments with error bars indicating 1 standard deviation.

Genetic code expansion was also used to produce pAkt1S308. The Akt enzyme
containing pSer308 had above background but low activity (Figure 3A). Western
blot analysis revealed a band co-migrating with full-length Akt but also a species
with an apparent MW of ~35 kDa (Figure S2.7). This could result either from
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degradation or premature truncation from stopping at UAG308, which would
produce a protein of 37.6 kDa. We adjusted our estimated rate for this enzyme by
accounting for the fraction of full-length pAkt1S308 in our preparation. Although it
is possible we underestimated the activity Akt1 with pS308 (Figure 2.3A), the
data show that pSer cannot substitute for pThr308 to produce optimally active
Akt1.

Figure 2.3 Activity of T308S and phosphomimetic Akt1 variants. (A) In
comparison to pAkt1T308 activity (black crosses), mutations of T308 to either D
(pink squares), E (green triangles), or pS (red diamonds) resulted in low but
above background kinase activity (inset). (B) Kinase activity was also measured
in the context of an unphosphorylated Akt1 (gray circles) with phosphomimetic
mutations S473D (green squares) and S473E (peach squares). All reported values
represent the mean of triplicate experiments with error bars indicating 1 standard
deviation.
2.4.3 Enzymatic activity of phosphomimetic Akt1 variants. We next tested the
activity of purified phosphomimetic Akt1 mutants (Figure S2.6). In these
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experiments, we programmed either Ser473 phosphorylation (Figure 2.2A) or unphosphorylated Ser473 (Figure 2.3A) and examined the effect of residue
substitutions at position 308. Replacement of Thr308 with Asp increased the
activity of pAkt1S473 by a modest 2-fold (from 2.5 to 4.6 fmol/min/pmol Akt),
resulting in enzyme that displayed only 10% of the activity of doublyphosphorylated enzyme (Figure 2.2A, S2.6, Table 2.1). Surprisingly, replacing the
Thr308 with an Ala eliminated the activity of the mono-phosphorylated pAkt1S473
(Figure 2.2A), demonstrating that Ala308 is not an appropriate substitute for unphosphorylated Thr.
In the context of Akt1 that was not phosphorylated at Ser473 (Figure 2.3B),
Akt1D308 demonstrated 5-fold higher enzyme activity in comparison to unphosphorylated Akt1, but this was still ~100-times lower than that of pAkt1T308
(Figure 2.3A, S2.6, Table 2.1). Akt1E308 was >200-fold less active than pAkt1T308
(Figure 2.3A, S2.6). Interestingly, production of pAkt1S308 by our genetic code
expansion approach resulted in an enzyme with only 3-fold more activity than
Akt1D308 (Figure 2.3A), suggesting that Asp308 may, to some extent, mimic
pSer308, but not the natural pThr308 residue in Akt1.
Phosphomimetic substitution at Ser473 also failed to activate Akt1. We tested
Ser473 mutations in the context of un-phosphorylated Akt1 (Figure 2.3B, S2.6)
and in Akt1 variants phosphorylated at Thr308 (Figure 2.2B). For unphosphorylated Akt1, we examined the effect of Asp and Glu substitutions at
position 473 (Figure S2.6). Substitution with Asp at position 473 lead to
essentially inactive enzyme (Figure 2.3B, S2.6, Table 2.1). Replacement of Ser473
with Glu resulted in an insignificant increase above the activity of unphosphorylated Akt1 enzyme (Figure 2.2C, S2.6, Table 2.1). In the context of
pAkt1T308 (Figure 2.2B), phosphomimetic mutations (D and E) failed to stimulate
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activity above pAkt1T308 with S473. Indeed, all S473 variants reduced pAkt1T308
activity with S473A showing the most significant reduction (Tables 2.1, 2.2).

2.4.4 Akt1 mutant activity in live cells. Having assessed the Akt mutants in vitro,
we examined the activity of Akt1 phosphorylation site mutants in live cells. To
this end, we utilized our quantitative FRET-based kinase activity reporter, BKAR,
and examined Akt signaling (36). Co-expression of kinase constructs with FRETbased activity sensors affords a sensitive assay for examining agonist-evoked
signalling in a cellular context (41). As the response to endogenous Akt activity is
so low, it provides an ideal system to evaluate signaling by introduced Akt
variants as a significant response can be observed from the overexpressed kinase.
Serum-starved COS-7 cells expressing BKAR and mCherry-tagged Akt
variants were stimulated with epidermal growth factor (EGF) followed by Akt
inhibition with GDC 0068. In real time, we monitored resulting changes in the
BKAR FRET ratio (CFP/FRET) that are reflective of cellular Akt activity (Figure
2.4A). For these experiments, cells selected for analysis had comparable levels of
Akt1 expression as assessed by quantifying mCherry levels; thus, in this system,
one can clearly compare the relative signaling competence between wild type
and mutant Akt. We have documented previously that the mCherry tag does not
significantly impact Akt1 activity (41).
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Figure 2.4 Cellular activity of Akt1 variants. (A) Serum-starved COS-7 cells
expressing BKAR alone (gray) or BKAR with Cherry-tagged Akt WT (blue),
T308A (orange), T308D (purple), S473A (green), S473D (red), or T308D, S473D
(DD, yellow) were imaged, stimulated with EGF, and then treated with the Akt
inhibitor GDC 0068. Multiple cells were included from at least two independent
experiments for analysis. FRET ratios from each cell were normalized and their
average plotted over time. Error bars represent SEM. (B) Following a 10-minute
treatment with EGF, lysates from serum-starved COS-7 cells expressing the
indicated Cherry-tagged Akt were analyzed by Western blotting for Akt
activation using phospho-specific antibodies toward the activation loop (α-p308)
and hydrophobic motif (α-p473). The asterisk (*) marks migration of Cherry-Akt
and the hyphen (-) marks endogenous Akt. (Experiment by Maya Kunkel)
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Overexpression of wild type (WT) Akt1 resulted in a significant BKAR
response to EGF treatment compared to the response observed from endogenous
Akt (Figure 2.4A, blue vs. grey trace). Interestingly, despite the level of
overexpressed Akt in these experiments being in vast excess compared to
endogenous Akt, substitution of either the non-phosphorylatable Ala or the
‘phosphomimetic’ Asp or Glu at the Thr308 site yielded an Akt1 enzyme that
displayed no signaling in the cell (Figure 2.4A, orange and purple traces, Figure
S2.8). These data establish the requirement of pThr308 for detectable Akt1
activation in cells and show that T308D is not a constitutively active Akt1 variant.
In contrast to the strict requirement for phosphorylation at Thr308, either Ala,
Asp or Glu substitution at the Ser473 site were tolerated without detrimental
effects on cellular Akt activity as assessed using BKAR (Figure 2.4A, green and
red trace, Figure S2.8). Importantly, a double mutation of both 308 and 473 to Asp
resulted in an inactive enzyme. Thus, the activity of Akt mono-phosphorylated at
Thr308 is necessary and sufficient for maximal signaling in the context of cells.

2.4.5 Mutant Akt1 kinases are phosphorylated following EGF stimulation. We
next examined the phosphorylation state of Thr308 and Ser473 of the mutant Akt
kinases in our cell-based assay (Figure 2.4B). In experiments in Figure 2.5, we
reduced the expression of the tagged Akt variants to be equivalent to the
endogenous Akt expression level as determined by Western blot. EGF
stimulation (all even numbered lanes) induced phosphorylation of both
endogenous and wild-type Akt1 (lane 4) as assessed by Western blot (Figure 2.5).
Importantly, phosphorylation of Thr308 in the Ser473 mutants (lanes 10 and 12)

51
was at the same level as the WT Akt1 (lane 4) demonstrating that PDK1
phosphorylation downstream of PI3K signaling was intact. Analysis of Ser473
phosphorylation revealed that, while this site was phosphorylated downstream
of PI3K signaling, the level of phosphorylation at Ser473 was reduced in the
T308A and T308D mutants (lanes 6 and 8) compared to WT Akt1 (lane 4). This
suggests that lack of phosphate on Thr308 impairs phosphorylation of Ser473.
Even though the level of Ser473 phosphorylation was reduced in these mutants,
the level of total overexpressed Akt protein was saturating in Figure 2.4A. Given
the excessive amount of Akt overexpressed in the experiments in Figure 2.4A,
this lack of activity observed using BKAR indicates that T308A, T308D and T308E
(Figure S2.8) are clearly not able to signal, and any catalytic activity observed in
these variants is below the threshold to result in detectable cellular activity.
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Figure 2.5 Reduced, but active, signaling from Akt T308S. (A) Serum-starved
COS-7 cells expressing BKAR with or without minimally detectable levels of
Cherry-tagged Akt were imaged during stimulation with EGF followed by
treatment with the Akt inhibitor GDC 0068. Normalized average FRET ratios for
WT (blue), T308S (red) and T308S, S473A (green) in comparison to BKAR alone
(gray) are shown. Data were analyzed from cells expressing equal low levels of
Cherry-Akt. Multiple cells were included from at least two independent
experiments. FRET ratios from each cell were normalized and their average
plotted over time. Error bars represent SEM. (B) Following a 10-minute treatment
with EGF, lysates from serum-starved COS-7 cells expressing the indicated
Cherry-tagged Akt were analyzed by Western blotting for Akt activation using
phospho-specific

antibodies

toward

the

activation

loop

(α-p308)

and

hydrophobic motif (α-p473). The asterisk (*) marks migration of Cherry-Akt and
the hyphen (-) marks endogenous Akt. (Experiment by Maya Kunkel)
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2.4.6 Impact of Ser substitution at Thr308 in cells. As the recombinant Akt1D308
had similar activity as the pAkt1S308 protein in vitro, we were interested to
examine the impact of Ser at 308 in the overexpressed mCherry-Akt system using
BKAR. Overexpression of mCherry-Akt-T308S resulted in a similar BKAR
response to that of WT Akt1 (data not shown). As this imaging system is
monitoring an excess of the overexpressed mutant Akt, we attempted to express
reduced levels of the kinase in order to discern whether there was a difference in
cellular activity between WT Akt1 and Akt1 with Ser at position 308. Indeed,
titrating down the expression levels and selecting for the lowest expressing cells
based on mCherry intensity, we observed a reduction in Akt1 signaling output
from the Ser308 enzyme compared to the WT enzyme with Thr308 (Figure 2.5A,
blue and red traces). In the impaired kinase (Akt1S308), we then substituted the 473
site with Ala (Ser308, Ala473), however, even in the context of an impaired Akt
kinase, mutation of the 473 site did not influence Akt signaling (Figure 2.5A,
green trace). Under the same conditions noted here to analyze minimal levels of
overexpressed kinase, we were unable to detect a reduced level in signaling from
the S473A mutant compared to WT Akt1. This result is in agreement with our
observations that mutation of Ser473 to Ala in the context of Akt1
phosphorylated at residue 308 either on Thr (Figure 2.4, green trace) or Ser
(Figure 2.5, green trace) does not impact signaling in cells. Furthermore, the data
indicate that the ability of pAkt1T308 S473A to signal is greater than that of Akt1
T308S.
Western blot analysis confirmed that phosphorylation of the 308 site (even
with a Ser substitution) was intact following EGF stimulation (Figure 5B). Our
data in live cells indicate that phosphate, specifically, not an acidic residue, at
position 308 is the most critical component to induce Akt activity. In the cell, as
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we found in vitro, phosphomimetic substitutions of Asp or Glu at the 308 site are
unable to propagate Akt signaling, and, in agreement with our enzymatic data,
substitution of Thr308 to Ser leads to reduced Akt activity and signaling.

2.5 Discussion
Using genetic code expansion and enzymatic phosphorylation, we
produced fully active Akt1 directly from E. coli for the first time. We validated
our biochemical findings in cells using a genetically-encoded reporter for Akt
signaling. This allowed us to 1) measure the specific activity of Akt1 sitespecifically and exclusively phosphorylated at either or both regulatory sites,
Thr308 and Ser473, 2) systematically examine the role of phosphate at each site in
modulating the intrinsic catalytic activity of the pure enzyme, and 3) examine the
effectiveness of amino acid substitutions to mimic phosphorylated or unphosphorylated residues in cells.

2.5.1 Generation of active Akt1. We demonstrated the compatibility of
enzymatic

phosphorylation

with

genetically-encoded

phosphoserine

incorporation by producing site-specific and doubly-phosphorylated Akt1
(Figure 2.1A). This was achieved by co-expressing the upstream kinase PDK1, to
induce Thr308 phosphorylation, and simultaneously genetically encoded pSer473
in Akt1. To our knowledge, this is the first demonstration of protein production
in E. coli with programmed pSer and pThr residues in the same protein.
Consistent with numerous studies (24), our in vitro kinase assays revealed robust
activity of ppAkt1 activity in the absence of PIP3, suggesting PIP3 is not required
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for Akt1 activity per se. This contradicts a recent study proposing that PIP3
binding may be essential for both Akt1 activation and activity in cells (42). As
noted above, producing site-specifically and doubly phosphorylated, and thus
fully-activated Akt1 has previously not been achieved via recombinant
expression in vivo in E. coli given the complicated nature of Akt activation by
multiple kinases, chaperones, and lipid second messengers (24). Our experiments
demonstrate a novel approach, taking advantage of genetic code expansion and
enzymatic phosphorylation, that overcomes the existing limitations in both
methods to produce fully-active human kinases.

2.5.2 Role of phosphorylation in activating Akt1. The kinetic mechanisms of Akt
activation by phosphorylation are less well characterized relative to other kinases
such as PKA (43) and PKC (44), stemming in part from the difficulty in obtaining
Akt

in

specifically

phosphorylated

forms.

Most

studies

relied

on

immunoprecipitating Akt from unstimulated and growth factor-stimulated cells.
Akt1 activity is then determined using a kinase activity assay in the
immunoprecipitates. Such studies typically report a 10–50-fold stimulation of the
activity of Akt immunoprecipitated from growth factor-treated compared to
unstimulated cells, e.g., (45-49). Alessi and co-workers showed that Akt1 had 45fold higher activity when immunoprecipitated from cells treated with IGF-1
compared to untreated cells (6). In the context of an Akt1 mutant with Ala
present at position 473, the increase was only 5-fold, and if Ala was present at
position 308, there was essentially no stimulated activity. Similar results were
reported by Hemmings and coworkers for Akt3 (50). These data are qualitatively
similar to the results from our study, yet our quantitative analysis defines Thr308
as the critical regulator of Akt activity and its phosphorylation alone increases
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activity to approximately one-third that of the doubly-phosphorylated enzyme.
Our unique ability to produce recombinant fully-phosphorylated Akt1 from
bacteria has revealed that specific phosphorylation at both regulatory sites
increases the intrinsic catalytic activity by over three orders of magnitude,
defining the stringency with which Akt signaling is ‘silent’ in the absence of
agonist stimulation and the resulting phosphorylation of Akt.
Several lines of evidence support our finding that phosphorylation of Thr308,
but not Ser473, is necessary and sufficient for the activation of the intrinsic
catalytic

activity

of

Akt.

First,

Vogt

and

colleagues

concluded

that

phosphorylation of this site, but not Ser473, was sufficient for the oncogenic
potential of Akt (26). Specifically, they showed that mutating Thr308 prevented
the phosphorylation of Akt substrates and transformation of chicken embryonic
fibroblasts. Secondly, Jacinto and coworkers showed that in cells lacking
mTORC2, Akt was not phosphorylated on Ser473, yet retained the ability to
phosphorylate a subset of Akt substrates (14). Based on this and other reports
from the literature, phosphorylation of Ser473 was suggested to determine
substrate specificity of Akt. Supporting a role of Ser473 in the cellular function of
Akt, loss of phosphorylation of this site by overexpressing the PH domain
Leucine-rich repeat Protein Phosphatase (PHLPP) (which dephosphorylates
Ser473) results in increased apoptosis (51) and, conversely, enhancing
phosphorylation at Ser473 by depletion of PHLPP results in suppression of
tumors in a xenograft model. Although these effects on apoptosis may arise from
non-Akt functions of PHLPP (52), they support a role of Ser473 phosphorylation
in Akt biology. Phosphorylation at Ser473 may function to tune rather than
activate Akt signaling. However, our results establish that the phosphorylation
state of Thr308 is a superior read-out for the activation state of Akt. Whereas

57
phosphorylation at Thr308 alone is able to activate Akt1, phosphorylation of
Ser473 alone leads to relatively weak activity in vitro, and no detectable activity in
the cell. Neither the Asp308 nor Glu308 Akt1 mutants had EGF-stimulated
activity in cells. Although the pAkt1S473 Thr308Asp mutant had 10% of the
activity of the doubly-phosphorylated Akt1 in vitro (Table 2.2), we observed no
cellular Akt1 activity and impaired Ser473 phosphorylation in Akt1 variants with
Asp, Glu or Ala mutations at position 308. Even if these variants are active in the
cell, the low intrinsic activity of the Asp308 mutant, for example, may be too low
to overcome the opposing de-phosphorylation reaction catalyzed by cellular
phosphatases acting on Akt substrates, including the BKAR reporter. Akt1
Thr308Asp mutants can no longer be regarded as constitutively active Akt1
variants (30-32).
The phosphorylation status of Akt1 is indeed clinically relevant. Whereas
pSer473 is the most commonly used biomarker (53,54), pThr308 was identified as
a better prognostic biomarker in human non-small cell lung cancer (55) and acute
myeloid leukemia (56). Our study underscores the relevance of examining the
phosphorylation state of Thr308 as a general marker for the activation state of
Akt in basic research and clinical settings.
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Table 2.2 Akt enzyme activity comparison in vitro and in COS7 cells

Akt1 activity

Akt1 sites
308

473

in vitro (%)

in cell

pThr

pSer

100

Thr

Ser

<1

N.D.

pThr

Ser

27

N.D.

pThr

Asp

24

+

pThr

Glu

15

+

pThr

Ala

9

+

Thr

pSer

5

N.D.

Asp

pSer

10

0

Glu

pSer

N.D.

0

Ala

pSer

<0.001

0

pSer

pSer

N.D.

pSer

Ser

1

pSer

Ala

N.D.

Thr

Asp

<1

N.D.

Thr

Glu

<1

N.D.

Asp

Ser

<1

N.D.

Glu

Ser

<1

N.D.

+

+*
N.D.
+*

Enzyme activity determined biochemically is given as a percentage of the
maximally active ppAkt1. Agonist-evoked enzyme activity in cells is denoted by
a plus (+) sign. No detectible activity is denoted by zero (0). N.D. Not determined.
*Observed a reduced response compared to WT when the Akt1 mutant indicated
was expressed at a reduced level, similar to the level of endogenous Akt (Figure
3B).

59
2.5.3 Acidic residues do not function as phosphomimetics in Akt1. Koshland
and colleagues first introduced the use of acidic amino acids to mimic phosphate,
showing that an Asp mimicked the functional effect of phosphate to inactivate
isocitrate dehydrogenase (57). There are other examples where the negative
charge of the amino acid effectively mimics that of phosphate and, indeed, nature
has used the trick in reverse: it is estimated that 5% of pSer sites may have
evolved from an ancestor with Glu or Asp at the homologous position (34).
However, acidic residues are not necessarily ‘phosphomimetics’: their negative
charge, hydration sphere, and size are considerably different from a
phosphorylated Ser or Thr residue. Acidic amino acids have a net negative
charge of 1 compared to 2 for phosphate at neutral pH, the hydration sphere is 4
waters compared to 14 for phosphate, and their volume is considerably smaller
than the phospho-amino acids they replace.
Because kinases are often activated by phosphorylation, Glu and Asp
mutations are routinely used to mimic the function of phosphorylated serine or
threonine residues in many kinases (33), including Akt1 (26,29). Our current
study reveals that acidic residues do not mimic phosphorylation in Akt1. This is
an

important

finding

given

the

widespread

and

continued

use

of

phosphomimetics in interrogating Akt signaling, and kinase signaling generally,
in cells. The phosphomimetic variants that were active in our assays are 30 to
210-fold less active than their monophosphorylated counterparts. Based on our
data in live cells, Thr308 phosphomimetic variants fail to activate Akt signaling
(Figure 2.4A). Although, Akt1 Thr308Asp was the most active of the
phosphomimetic mutants in vitro, this level of activity is insufficient to produce a
cellular response. This result is consistent with a study from Vogt and colleagues
who reported that Thr308Asp was an ‘unsuitable’ substitution for pThr308
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(26,29).

Their

data

showed

that

Akt

Thr308Asp

did

not

cause

the

phosphorylation of cellular Akt substrates such as GSK-3β nor did it induce
oncogenic transformation, functions that were robustly mediated by wild-type
Akt. Nonetheless, phosphomimetics constructs of Akt pervade the literature on
Akt signaling mechanisms. Because phosphomimetics do not result in
physiologically relevant activation of the kinase activity of Akt, it is possible that
any biological effects of such mutations may arise from scaffolding functions or
non-catalytic mechanisms, as increasingly described for protein kinase family
members (58).
An interesting finding from our study is that pSer is not well tolerated at
position 308. According to the in vitro kinase assays, pAkt1S308 is more active than
phosphomimetic 308 mutants, yet pAkt1T308 is ~25-fold more active than pAkt1S308.
Furthermore, when phosphorylated post-translationally in the cell, pAkt1S308 also
showed reduced activity compared to that of pAkt1T308. To the best of our
understanding, there is no literature-based evidence on the effect of pS308 on the
activation of Akt1 in vivo or in vitro. Our results indicate that the γ-methyl group
of Thr308 optimally positions the phosphate to create the ordered hydrogenbonding network between the phosphate of pThr308, His194 and Arg273, which
facilitates the binding to ATP and substrate at the Akt1 active site (26). Indeed,
this observation is supported by crystallographic structures of Akt in partially
active form and in complex with substrate peptide and an ATP analog (59,60).
The structure shows pThr308 is involved in salt bridge interactions with Arg273
and Lys297, and a water-mediated hydrogen bond with His194 is also evident
(Figure 2.6). In the structure, steric complementarity can be seen between the γmethyl of pThr308 and Cys310 (Figure 2.6B). In agreement with our cell-based
and biochemical data, the structure suggests the interaction between the γ-
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methyl of pThr308 and Cys310 optimally orients the phosphate for interaction
with is positively charged counterparts in the salt bridges. We hypothesize that
pS308, which lacks this methyl group, will rotate more freely in the active site,
perhaps shifting the enzyme in and out of its active confirmation.
Our study also revealed that Ala is not a mimic of un-phosphorylated Thr308.
Ala at position 308 resulted in a 10-fold reduction in the basal activity of Akt1
mono-phosphorylated at Ser473. Taylor and colleagues also found that Ala at the
activation loop of protein kinase A (PKA) results in a more severe kinetic defect
compared to having an un-phosphorylated Thr at the activation loop (61,62). The
detrimental effect of Ala may arise from a loss of hydrogen bonding ability. The
Ala mutation favors a helical conformation of the activation loop that may also
drive structural ensembles away from the active conformation or it may favor an
inhibited conformation due to interactions with other domains or proteins (A.
Kornev and S. Taylor, personal communication).
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Figure 2.6 Structure of human Akt in complex with GSK-3β substrate peptide.
(A) Structure of the active human pAktT308 (S473D) kinase domain (gray, cartoon)
shown in complex with GSK-3β peptide (purple) and a non-hydrolyzable ATP
analog (ATP’ = AMP-PNP). The target of Akt1 phosphorylation on the GSK-3β
substrate peptide is indicated (*). Key residues are labeled and in addition to the
regulatory phosphorylation sites (pThr308, and phosphomimetic mutation
S473D), other Ser/Thr phosphorylation sites are highlighted (yellow). (B) A 90°
rotated and close up view of the Akt1 active site, focused on the position of
pThr308. The phosphate at position 308 makes extensive salt bridge interactions
with Arg273 and Lys297; pThr308 also participates in a water mediated hydrogen
bond network with His194. The Cγ methyl group on pThr308 forms a
hydrophobic interaction with Cys310 as indicated in the van der Waals surface
representation (transparent). The figure includes structural data from PDB codes
3CQU (59) and 1O6K (60).

2.5.4 Akt1 activation threshold in cells. Live cell imaging experiments revealed
that all forms of Akt1 that had phosphorylation of Thr at position 308 had
maximal signaling output following EGF stimulation of cells, regardless of the

63
amino acid at position 473 (Table 2.2). In contrast, no activity was observed if the
residue at position 308 was not phosphorylated, regardless of the amino acid at
position 473 (Table 2.2). Based on in vitro data, we can estimate a threshold to
observe Akt activity in cells: our in vitro studies reveal that phosphorylation of
Ser473 alone stimulated Akt1 activity 80-fold over the un-phosphorylated
enzyme, yet this level of Akt1 activity is apparently below the threshold required
to elicit Akt1 signaling in the cell. In vitro, the activity of mono-phosphorylated
Akt1 at Thr308 was reduced by less than 3-fold compared to the maximallyactive and doubly-phosphorylated enzyme, and this level of activity is sufficient
for maximal signaling output in cells. In addition, pAkt1T308 S473A was 10-fold
less active than the doubly phosphorylated enzyme, yet this enzyme was
sufficient for robust Akt1 signaling in the cell. Taken together, our data suggest
that Akt1 variants whose intrinsic catalytic activity is greater than ~10% that of
doubly phosphorylated enzyme are robustly active in cells. This novel finding
further suggests that in cells only a fraction of Akt needs to be activated by
phosphorylation for full Akt-dependent signaling.
Although previous reports have identified a 10-fold activity increase
associated

with

stoichiometry

of

Ser473

phosphorylation

phosphorylation

was

in

immuno-precipitates,

unknown

(6).

Furthermore,

the
the

phosphorylation state of Akt1 may differentially impact substrates based on the
local concentration or abundance of the substrate. For example, if Akt1 is poised
on a scaffold and co-localized with substrate, a lack of Ser473 phosphorylation
may be irrelevant as the local concentration of substrate is high. For
phosphorylation of an untethered or low abundant substrate, that 3-fold
difference in activity may reduce or eliminate Akt1 signaling in a substratespecific manner. Indeed, previous work suggested that phosphorylation at Ser473
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may increase the activity of Akt1 for particular substrates, e.g., FoxO1/3a (14), yet
significant future efforts are required to define the impact of Akt1
phosphorylation status on substrate selectivity.
Mutation and phosphorylation state can impact Akt1 activity directly, but
also indirectly by altering the accessibility of phosphatases. For example,
previous studies showed that Ala substitution in PKC at the hydrophobic motif
increased phosphatase sensitivity of PKC at additional sites (63). Our finding that
Akt1 mutants with very low activity did not signal in cells suggests that localized
activation needs to exceed a threshold to outcompete phosphatases in the cellular
environment. Thus, the dynamic range of Akt signaling in a cell is such that
sufficient Akt needs to be activated to overcome phosphatase suppression, but
additional changes in phosphorylation site occupancy may or may not be needed
for maximal signaling, particularly if localized to protein scaffolds and
microdomains (64).

2.6 Conclusion
We established a robust protocol to generate and characterize fully active and
differentially active Akt1 variants. These Akt1 variants will next be employed as
a unique set of tools to investigate Akt1 substrate specificity and to screen for
potential drug candidates against the most potent and active forms of the
oncogenic kinase. The ability to produce optimally active Akt1 will have broad
implications for drug discovery efforts, as we hypothesize that drug screening
against a fully active Akt1 enzyme will more likely produce a potent and
selective inhibitor.
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We presented a systematic study of the impact of phosphorylation and
phosphomimetic substitutions on the activity of Akt1 in the test tube and in
living cells. Our data suggest that phosphomimetic substitutions should be tested
for their ability to mimic phosphorylation, and Ala substitutions should also be
assessed for their ability to act as non-phosphorylatable counterparts. We found
these common assumptions simply do not hold for Akt1 and complementary
experiments in vitro and in the cell were invaluable in reaching this conclusion.
Viewing the cell-based assays in isolation of the kinase activity data may have led
to the erroneous conclusion that phosphomimetic substitution at 473 supports
full Akt1 activity. Rather the situation in the cell is more complex.
Phosphorylation at 308 alone is sufficient to observe maximal Akt1 signaling, and
mutation of 473 to Ala, Asp or Glu had no apparent impact on Akt1 activity in
the cell. In the test tube, we determined that phosphomimetics fall far short of
activating Akt1 to the same extent as true phosphorylation at both regulatory
sites. Indeed and counter-intuitively, we found that Thr308Asp is a good mimic
of a lack of phosphorylation at 308, while Thr308Ala is a kinase-dead enzyme that
is not active in vitro despite phosphorylation at 473. In the cell, only true
phosphorylation at 308 led to observable activity, suggesting that mimics of pThr
are particularly inappropriate at this site. Interestingly, pSer308 shows reduced
activity, which was still sufficient to observed Akt1 signaling in the cell. The data
demonstrate conclusively that pSer is a far better mimic of pThr than Asp or Glu
phosphomimetic substitutions.
The foregoing experiments reveal that phosphorylated Thr308 is necessary,
sufficient, and irreplaceable for activation of Akt in vitro and in cells. We showed
that no other residue is tolerated at that site, including acidic amino acids, which
are frequently used as ‘phosphomimetics’. Our findings also question the
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generally assumed validity of using Ala mutation to mimic a nonphosphorylated form of residues like Ser and Thr. In total, our results beg caution
in using amino acid substitutions to examine the role of phosphorylation in
protein function and in the biology of cell signaling.
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2.8 Supporting information:
2.8.1 Supporting experimental procedures
Bacterial strains and plasmids
The human akt1 gene was purchased from Harvard PlasmidID repository service
(Boston, MA, USA) and subcloned (NdeI/BamH1) into an IPTG (isopropyl β-D-1thiogalactopyranoside) inducible T7 promoter driven expression vector (pDS1)
(38). In addition, the akt1 gene was subcloned (NcoI/NotI) into T7lac promoter
preceded pCDFDuet-1 vector. PDPK1 gene, which was also purchased from
Harvard PlasmidID repository service, was subcloned (KpnI/NdeI) into the
second cloning site of pCDFDuet-1. The codons for Ser and Thr residues in akt1 at
positions Ser473 and Thr308, were mutated to amber (TAG), Asp (GAC) and Glu
(GAG) codons using site-directed mutagenesis according to previously described
methods(65). Successful cloning was verified by DNA sequencing (London
Regional Genomics Centre, London, ON, Canada and Genewiz, Cambridge, MA,
USA).

Protein and phosphoprotein production. Recombinant proteins were expressed
in BL21(DE3) (Invitrogen). Phosphoproteins were produced using 2nd generation
mutants of the pSer incorporation system (SepRS9, EFSep21) (66). The system is
encoded on the pDS-pSer2 plasmid (described previously (38)), which contains 5
copies of tRNASep, SepRS9 and EFSep21. pDS1 and pDS-pSer2 plasmids for
phosphoprotein expression were co-transformed into E. coli Bl21(DE3) and plated
on LB-agar plates with 25 µg/ml kanamycin and 100 µg/ml ampicillin. A single
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colony was used to inoculate 70 ml of LB (with ampicillin 100 µg/ml, kanamycin
25 µg/ml), which was grown, shaking, overnight at 37°C. From this starter
culture, a 10 ml inoculum was added to 1 l of LB medium with antibiotics (as
above) and O-phospho-L-serine (pSer, 2.5 mM final concentration, Sigma Aldrich).
These cultures were grown at 37°C until OD600 = 0.6 at which point 2.5 mM of
additional pSer was added to the culture. Protein expression was induced by
adding 300 µM of IPTG at OD600 = 0.8. Cultures were further incubated at 16°C
for 18 h. The same protocol was used in producing pAkt1 variants from
pCDFDuet-1 construct, except that here streptomycin (50 µg/ml) was used as the
antibiotic to maintain pCDF. In expressing phosphomimetic proteins, ampicillin
at a concentration of 100 µg/ml was used and no pSer was added to the cultures.

Affinity column chromatography. The His-tagged proteins were purified using
Ni affinity column chromatography. 0.5 ml of Ni-NTA resin (Thermo-Fisher
Scientific) was used for 1 l of E. coli culture. The cell lysates (see Methods) were
loaded into the column and washed extensively with wash buffer A (20 mM
Hepes, 150 mM NaCl, 3 mM β-mercaptoethanol, 3mM Dithiothreitol, 1 mM
Na3VO4 and 5 mM NaF, 15 mM Imidazole) followed by wash buffer B (20 mM
Hepes, 150 mM NaCl, 3 mM β-mercaptoethanol, 3mM DTT, 1 mM Na3VO4 and 5
mM NaF, 20 mM Imidazole). Protein was eluted using an elution buffer (20 mM
Hepes, 150 mM NaCl, 3 mM β-mercaptoethanol, 3mM dithiothreitol, 1 mM
Na3VO4 and 5 mM NaF) with 75 mM Imidazole. The same protocol was used for
Akt1 variants with phosphomimetic mutations except: 1) phosphatase inhibitors
were excluded from the buffers, 2) the imidazole concentrations of the wash
buffers were 20 - 50 mM, and 3) the imidazole concentration of the elution buffer
was 200 mM. Fractions were run on 10% SDS (sodium dodecyl sulfate) poly-
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acrylamide gels. Akt1 variants were further purified by size exclusion
chromatography.

Size exclusion chromatography. Purification was performed in AKTA Pure L1
FPLC system (GE Healthcare, Little Chalfont, UK) using Superdex200 (GE
Healthcare Uppsala, Sweden) gel filtration column equilibrated with buffer (25
mM HEPES pH 7.0, 100 mM NaCl, 0.25 mM Tris(2-carboxyethyl)phosphine
(TCEP)). The flow rate was maintained at 0.1 ml/min and 1 ml fractions were
collected. Fractions were run on 10% SDS-PAGE and pure fractions were pooled
and concentrated using Vivaspin 6 (6 ml, 10 kDa, GE Health Care,
Buckinghamshire, UK) or Amicon ultra (0.5 ml, 3 kDa, Merk Millipore Ltd., Cork,
Ireland) concentration units. Protein concentrations were determined using
Bradford assay and samples were stored in aliquots at -80°C in storage buffer (20
mM HEPES pH 7.0, 150 mM NaCl, 3 mM β-mercaptoethanol, 3mM DTT)
containing 50% glycerol until further analysis.

Western blotting. The purified proteins were denatured using standard SDS
sample buffer and run on a 10% SDS gel. The gel was blotted onto a
nitrocellulose membrane using Turbo-Blot Turbo transfer system (Bio-Rad). The
membrane was immunoblotted with mouse anti-histidine primary antibody (GE
Health Care Life Sciences) followed by anti-mouse horseradish peroxidase linked
secondary antibody (GE Health Care Life Sciences). Bands were visualized by
chemiluminescence and detected with Gel Doc XR plus (Bio-Rad).

77
Multiple Reaction Monitoring (MRM) of pAkt1S473. Following protein
purification, phosphorylated Akt protein was re-suspended in trypsin digestion
buffer (100 mM Tris pH 8.5, 1 mM CaCl2) and digested at a ratio of 20:1 w/w with
sequencing grade trypsin (Roche Diagnostics) overnight at 37°C. The digest was
then analyzed by positive electrospray ionization LC-MS/MS on a triple
quadruple mass spectrometer (4000 QTRAP AB Sciex, Concord, ON, Canada)
with Q3 used as a linear ion trap. A NanoAcquity UPLC system (Waters, Milford,
MA, USA) equipped with a C18 analytical column (1.7 µm, 75 µm × 200 mm) was
used to separate the peptides at the flow rate of 300 µl/min and operating
pressure of 8000 psi. Peptides were eluted using a 62 min gradient from 95%
solvent A (H2O, 0.1% formic acid) and 5% B (acetonitrile, 0.1% formic acid) to
50% B in 41 min, 6 min at 90% B, and back to 5% for 10 min. Eluted peptides were
directly electrosprayed (Nanosource, ESI voltage +2000V) into the mass
spectrometer. The instrument was set to monitor 49 transitions in each sample
with a dwelling time of 100 msec/transition. The in silico protease digest patterns
and the corresponding MRM-MS transitions were compiled with Skyline
software. Transitions that were larger than the precursor ion were selected on the
basis of the Skyline predictions and the specific b/y ions that allow unambiguous
identification of the selected phosphorylated Akt serine residues (Ser473) were
included. Akt peptides were monitored for serine phosphorylation, nonphosphorylated serine, as well as a serine deletion or mistranslation with
glutamine.

Parallel-Reaction Monitoring (PRM) of pAkt1T308. Following protein purification,
the Akt protein was precipitated in ice-cold acetone/ethanol/acetic acid (50/50/0.1,
vol/vol/vol). The protein precipitate was re-suspended in 8 M Urea, then reduced
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in 5mM dithiothreitol (DTT) at 37°C for 1h and alkylated in 14 mM
iodoacetamide (IAA) in darkness at room temperature for 1h. Unreacted IAA
was neutralized by adding 5 mM DTT in the suspension. The final protein
concentration was determined by Bradford assay. Glu-C digestion was
performed at 37°C overnight with a protein:Glu-C ratio of 20:1 w/w. The digest
was desalted in C18 column (Phenomenex) according to the manufacture’s
protocol and re-suspended in MS-grade water. A Q Exactive Hybrid Quadrupole
Orbitrap MS (Thermo Fisher Scientific) was used to analyze the peptides. Data
were analyzed using Skyline software.
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Figure S2.1 Production of purified full-length Akt1 and pAkt1 variants.
Following affinity chromatography, purified fractions from size exclusion
chromatography are visualized on SDS-PAGE. The Coomassie stained gel shows
successful purification of full-length Akt1 variants: un-phosphorylated Akt (lane
1), pAktT308 (lane 2), ppAktT308,

S473

(lane 3), AktT308D (lane 4), pAktS473 (lane 5),

pAktS473 T308A (lane 6), pAktS473 T308D (lane 7), AktS473D (lane 8). The ppAkt1
variant, likely due to its double negative charge, consistently runs slightly faster
than anticipated. We found this to be reproducible from 3 independent
preparations. MS/MS analysis confirmed the full-length ppAkt1 protein with the
expected protein sequence (Figure S2.2).

Figure S1
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Figure S2.2 Physical characterization of ppAkt1T308,

S473

479

. (A) Western blots of

His6-tagged un-phosphorylated Akt1 (lane 1), pAkt1T308 (lane 2), pAkt1S473 (lane 3),
and ppAktT308,

S473

(lane 4) with anti-his antibody. Mass spectra confirming

enzymatically phosphorylated ppAkt1T308,S473. PRM-MS/MS was used to identify
peptides with pT308 (B) and pS473 (C) in tryptic or GluC-digested samples of
ppAkt1T308,

S473

, we were unable to identify peaks corresponding to de-

phosphorylation or truncation of the ppAkt1. (D) Coverage map shows the
locations in the protein sequence where one or more significant tryptic or GluC
peptides were identified (blue line) by PRM-MS/MS in the ppAkt1T308, S473 sample.
Identified phosphorylation sites are indicated (P).
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Figure S2.3 Mass spectra confirming quantitative, genetically encoded pS473 in
Akt1. MRM-MS/MS was used to identify pS473 (A) but not Ser473 in a tryptic
digested sample of pure pAkt1S473 (A, B). MRM-MS/MS also identified a peptide
containing S473 (D) but not pS473 (C) in samples of purified and unphosphorylated Akt1 (C, D).
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Figure S2.4 Physical characterization of pAkt1T308. Mass spectra (A) confirming
enzymatically phosphorylated pAkt1T308. PRM-MS/MS was used to identify
Figure S3. Physical characterization of pAkt1T308. Mass spectra (A) confirming enzymatically
T308. MRM-MS was used to identifyT308.
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Figure S2.5 Activity of pAkt1T308 variants at reduced enzyme concentrations. A)
ppAkt1 and B) pAkt1T308 enzyme concentrations were reduced by 10-fold in order
to provide a sufficient linear phase to measure the reaction velocity accurately.
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Figure S2.6 Autoradiographs of γ-[
P]-ATP kinase assays with pAkt1 variants.
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Figure S2.7 Production of pAkt1S308. Fractions from affinity chromatography are
visualized on SDS-PAGE by anti-His immunoblot. Elution gradient of pAkt1S308
(lanes 1-5) with increasing imidazole concentrations.
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Figure S7. COS-7 cells co-expressing BKAR and equal levels of Cherry-tagged Akt's were imaged
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Akt were imaged and the CFP/FRET ratio examined following EGF stimulation
and Akt inhibition with GDC 0068 (GDC). Mutation of Thr308 to Glu resulted in
an inactive kinase (middle plot), whereas mutation of Ser473 to Glu did not

impair its activity (bottom plot). Data were normalized to the first 4 minutes and
plotted.

Graphs are representative of three independent experiments.

(Experiment by Maya Kunkel)
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Figure S2.9 Cellular activity of phospho-ablated Akt1 variant S473A. Serumstarved COS7 cells expressing BKAR with minimally detectable levels of Cherrytagged Akt were imaged during stimulation with EGF followed by treatment
with the Akt inhibitor GDC 0068. The average FRET ratios for WT (blue) and
S473A (yellow) are shown. Data were analyzed from cells expressing equal low
levels of Cherry-Akt (n=12 for WT and n=8 for S473A) from three independent
experiments. FRET ratios from each cell were normalized and their average
plotted over time. Error bars represent SEM. (Experiment by Maya Kunkel)
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Chapter 3

3

Phosphorylation-dependent

chemical

and

auto-

inhibition of Akt1

3.1 Abstract
Akt1 is a proto-oncogene that is over active in most cancers. Akt1 activation
requires phosphorylation at Thr308; phosphorylation at Ser473 further enhances
catalytic activity. Akt1 activity is also regulated via interactions between the
kinase domain and the N-terminal auto-inhibitory pleckstrin homology (PH)
domain. As it was previously difficult to produce Akt1 in site-specifically
phosphorylated forms, the contribution of each activating phosphorylation site to
auto-inhibition was unknown. Using a combination of genetic code expansion
and in vivo enzymatic phosphorylation, we produced Akt1 variants containing
programmed

phosphorylation

to

probe

the

interplay

between

Akt1

phosphorylation status and the auto-inhibitory function of the PH domain.
Deletion of the PH domain increased the enzyme activity for all three
phosphorylated Akt1 variants. For the doubly phosphorylated enzyme, deletion
of the PH domain relieved auto-inhibition by 295-fold. We next found that
phosphorylation at Ser473 provided resistance to chemical inhibition by Akti-1/2
inhibitor VIII. The Akti-1/2 inhibitor was most effective against pAkt1T308 and
showed 4-fold decreased potency with Akt1 variants phosphorylated at Ser473.
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The data highlight the need to design more potent Akt1 inhibitors that are
effective against the doubly phosphorylated and most pathogenic form of Akt1.

3.2 Introduction
Protein kinase B (Akt) is a human serine-threonine kinase and a member of
the AGC family of protein kinases (1,2). The pathway regulated by Akt is the
most commonly activated signaling pathway in human cancers (3). Given that
more than 50% of human tumors contain hyper-activated Akt (2), effective
inhibition of active Akt has the potential to treat several distinct cancers. There
are three Akt genes in humans, encoding the isozymes Akt1, Akt2, and Akt3. The
Akt1 isozyme has well established roles in many human cancers. Over-active
Akt1 is a hallmark of diverse human malignancies (3,4) and linked to reduced
survival outcomes (5,6). Indeed, Akt1 is a leading drug target in cancer (7,8).
Over 300 clinical trials are completed or underway that involve targeting the
Akt1 signaling pathway.
Akt1 is a key regulator of the phosphoinositide 3-kinase (PI3K)/Akt1
signaling cascade that controls cell growth and survival (1). In human cells, the
activation of Akt1 occurs in response to growth factor stimulation (Figure 3.1).
Following activation by a receptor tyrosine kinase at the plasma membrane,
phosphoinositide-3-phosphate kinase (PI3K) phosphorylates its immediate
downstream target, a lipid second messenger called phosphatidylinositol-4, 5bisphosphate (PIP2), converting PIP2 into phosphatidylinositol-3, 4, 5triphosphate (PIP3) (2). Membrane anchored PIP3 is a binding site for pleckstrin
homology (PH) domain-containing proteins such as Akt1 and one of the
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upstream kinases that activates Akt1, phosphoinositide dependent kinase 1
(PDK1) (9). Co-localization of Akt1 with PDK1 leads to partial activation of Akt1
by PDK1-mediated phosphorylation of Thr308 in the kinase domain of Akt1. Full
activation of Akt1 results from a second phosphorylation event at Ser473 in the
regulatory domain of Akt1 by mechanistic target of rapamycin complex 2
(mTORC2) (Figure 3.1).
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Figure 3.1 Simplified schematic of Akt1 activation via phosphorylation of sites
Thr308 and Ser473. The transition from Akt1’s inactive state (PH-in) to its fully
active state (ppAkt1T308/S473) requires the release of PH domain mediated autoinhibition. This release occurs when Akt1’s PH domain interacts with PIP 3 (PHout). In the PH-out conformation, Akt1 is more susceptible to phosphorylation at
Thr308 and Ser473 by PDK1 and mTORC2 respectively. Upon release from PIP3,
Akt1 distributes rapidly in the cytosol and translocates to the nucleus to
phosphorylate >100 cellular proteins(2,10).
Leveraging

our

ability

to

produce

Akt1

protein

in

specifically

phosphorylated forms (Figure 3.2), we recently quantified the precise
contribution of pThr308 and pSer473 to Akt1 activity in vitro and in mammalian
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cells (11). In studies with purified full length Akt1, we found that pAkt1T308
achieves 30% of the activity of the doubly phosphorylated kinase. We also
observed in COS-7 cells that pSer473 is dispensable for Akt1 signaling and
phosphorylation of Thr308 alone was sufficient for maximal Akt1 signal
propogation. These results indicated Thr308 phosphorylation status is a superior
biomarker for Akt1 activity (11) and called into question the frequent use of
Ser473 phosphorylation as a diagnostic marker for Akt1 activity in cancer
patients (12-15).
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The N-terminal PH domain is auto-inhibitory to Akt1 activity. Due to
previous roadblocks in preparing Akt1 with programmed phosphorylation(s),
there are no reports that measure the contribution of a phosphate at each key
regulatory site to the auto-inhibition of Akt1 by the PH domain. In the current
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model, Akt1 exists in an auto-inhibited (PH-in) and activated confirmation (PHout). In its auto-inhibited conformation (PH-in), the PH domain binds between
the N- and C-terminal lobes of the un-phosphorylated Akt1 kinase domain.
During growth factor-mediated activation of Akt1, the PH domain forms a new
interaction with PIP3 causing it to move outward from the now more accessible
kinase

domain.

This

PH-out

conformation

is

readily

activated

via

phosphorylation at Thr308 by PDK1 and Ser473 by mTORC2. Disruption of the
PH and kinase domain interaction was identified as a plausible cause of
increased Akt1 phosphorylation and subsequent activity in cancer (16).
Here we quantified the ability of the PH domain to auto-inhibit Akt1 variants
phosphorylated at either or both key regulatory sites Thr308 and Ser473. We
produced novel recombinant Akt1 variants lacking the PH domain (ΔPH-Akt1)
that also contained programmed phosphorylation at each site separately or with
both sites phosphorylated. In the context of full length phosphorylated Akt1
variants, we quantified the contribution of both regulatory phosphorylation sites
to chemical inhibition with the PH domain dependent allosteric inhibitor Akti1/2.

3.3 Materials and Methods
3.3.1 Bacterial strains and plasmids. We designed a codon optimized PH domain
deficient (ΔPH) human akt1 gene (residues 109-480), which was synthesized by
ATUM (Newark, California, USA). The ΔPH-akt1 gene was sub-cloned
(NcoI/NotI) into an isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible T7lac
promoter driven pCDF-Duet1 vector with CloDF13-derived CDF replicon and
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streptomycin/spectinomycin resistance (pCDF-Duet1-ΔPHAkt1). The PDPK1
gene was purchased from Harvard PlasmidID repository service (plasmid ID:
HsCD00001584, Boston, MA, USA) and sub-cloned (KpnI/NdeI) into the second
multi-cloning site (MCS) of pCDF-Duet-1. Full length pAkt1 variants were
produced from pCDF-Duet1 plasmids as described previously (11). The genetic
code expansion system for phosphoserine (pSer) is encoded on the pDS-pSer2
plasmid (11,17,18), which contains 5 copies of tRNASep (19), phosphoseryl-tRNA
synthetase (SepRS9), and elongation factor Tu mutant (EFSep21) (20).
Incorporation of pSer also required site-directed mutagenesis of the Ser473 codon
to TAG in the ΔPH-akt1 constructs. Successful cloning was verified by DNA
sequencing at the London Regional Genomics Centre (London, ON, Canada) and
Genewiz (Cambridge, MA, USA).

3.3.2 Protein and phosphoprotein production. Recombinant Akt1 protein
variants were expressed in BL21(DE3) (Invitrogen) (Figure 3.2). The pDS-pSer2
plasmid (18) was used as before (11) to incorporate pSer in response to a UAG
codon at position 473 in ΔPHAkt1 and full length Akt1 variants. To produce both
full length and PH domain deficient Akt1 variants containing pSer473 (Table
S3.1), the pCDFDuet-1 Akt1 bearing plasmid was co-transformed with pDS-pSer2
into E. coli Bl21(DE3) and plated on LB agar plates with 25 µg/ml kanamycin and
50 µg/ml streptomycin. To produce pAkt1T308 variants, a pCDF-Duet1 plasmid
containing both the Akt1 variant (multiple cloning site 2 (MSC 2)) and PDK1
(multiple cloning site 1 (MSC 1)) was transformed into E. coli BL21(DE3) and
plated on LB agar plates with 50 µg/ml streptomycin. To produce ppAkt1T308,S473
variants, a pCDF-Duet1 plasmid containing both the Akt1 variant (MSC 2) with a
TAG codon at position 473 and PDK1 (MSC 1) (11) was co-transformed with
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pDS-pSer2 into E. coli Bl21(DE3) and plated on LB-agar plates with 25 µg/ml
kanamycin and 50 µg/ml streptomycin.
In all cases, a single colony was used to inoculate 70 ml of LB (with
streptomycin 50 µg/ml and, if needed, kanamycin 25 µg/ml), which was grown,
shaking, overnight at 37 °C. From this starter culture, a 10 ml inoculum was
added to 1 L of LB with antibiotics (as above) and, for pSer473 containing
variants only, O-phospho-L-serine (Sigma Aldrich, Oakville, Ontario) was added
to a final concentration of 2.5 mM. The cultures were grown at 37 °C until OD600 =
0.6 at which point, for pSer473 containing variants only, 2.5 mM of additional
pSer was added to the culture. Protein expression was induced by adding 300
µM of IPTG at OD600 = 0.8. Cultures were then incubated at 16°C for 18 h. Cells
were grown and pelleted at 5000 × g and stored at -80°C until further analysis.
Akt1 protein variants were purified from the cell pellets using Ni-Nitrilotriacetic
acid affinity column chromatography (see Supplementary Methods).

3.3.3 Parallel-Reaction Monitoring Mass Spectrometry (PRM-MS) of ppAkt1.
The ppAkt1 protein produced as noted above and the commercially available
active Akt1 (Abcam, lot 1) were precipitated in ice-cold acetone/ethanol/acetic
acid (50/50/0.1, vol/vol/vol). The protein precipitate was re-suspended in 8 M
urea, then reduced in 5 mM dithiothreitol (DTT) at 37°C for 1 h and alkylated in
14 mM iodoacetamide (IAA) in darkness at room temperature for 1 h. Unreacted
IAA was neutralized by adding 5 mM DTT. The final protein concentration was
determined by Bradford assay. Glu-C digestion was performed at 37 °C
overnight with a Glu-C to-protein ratio of 1/20 (w/w). The digest was desalted in
C18 column (Phenomenex) according to the manufacture’s protocol and re-
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suspended in MS-grade water. A Q Exactive Hybrid Quadrupole Orbitrap MS
(Thermo Fisher Scientific) was used to analyze the peptides. Data were analyzed
using Skyline software.

3.3.4 MALDI-TOF/TOF Mass Spec Analysis. In-gel digestion was performed
using a MassPREP automated digester station (PerkinElmer). Gel pieces were destained using 50mM ammonium bicarbonate and 50% acetonitrile, which was
followed by protein reduction using 10 mM dithiotreitol (DTT), alkylation using
55 mM IAA, and tryptic digestion in 50 mM ammonium bicarbonate, pH 8.
Peptides were extracted using a solution of 1% formic acid and 2% acetonitrile
and lyophilized. Prior to mass spectrometric analysis, dried peptide samples
were re-dissolved in a 10% acetonitrile and 0.1 % trifluoroacetic acid solution.
MALDI matrix, a–cyano–4–hydroxycinnamic acid, was prepared as 5 mg/ml in 6
mM ammonium phosphate monobasic, 50% acetonitrile, 0.1 % trifluoroacetic acid
and mixed with the sample at 1:1 ratio (v/v). Mass Spectrometry data (Figure
S3.1) were obtained using an AB Sciex 5800 MALDI TOF/TOF System
(Framingham, MA, USA). Data acquisition and data processing were done using
a TOF TOF Series Explorer and Data Explorer (both from AB Sciex), respectively.
The instrument is equipped with a 349 nm Nd:YLF OptiBeam On-Axis laser. The
laser pulse rate is 400 Hz. Reflectron positive mode was used. Reflectron mode
was externally calibrated at 50 ppm mass tolerance and internally at 10 ppm.
Each mass spectrum was collected as a sum of 500 shots.

3.3.5 Akt1 kinase activity assay. The activity of each Akt1 variant was
characterized by performing kinase assays in the presence of 200 µM substrate

96
peptide CKRPRAASFAE (SignalChem, Vancouver, BC, Canada) derived from
the natural Akt1 substrate, glycogen synthase kinase (GSK-3β). Assays were
performed in 3-(N-morpholino)propanesulfonic acid (MOPS, 25 mM, pH 7.0), βglycerolphosphate (12.5 mM), MgCl2 (25 mM), ethylene glycol-bis(β-aminoethyl
ether)-N,N,N',N'-tetraacetic acid (EGTA, 5 mM, pH 8.0), EDTA (2 mM), ATP
(0.02 mM) and 0.4 µCi (0.033 µM) γ-[32P]-ATP in a 30 µl reaction volume.
Reactions were incubated at 37 °C and time points were taken over 30 min time
courses. As previously (11), reactions were initiated by the addition of 18 pmol of
the indicated Akt1 variant to yield a final enzyme concentration of 600 nM and
quenched by spotting on P81 paper (21). For highly active Akt1 variants, the level
of Akt1 was titrated to identify a linear range to accurately determine initial
velocity (vo) (Figure S3.2). For this reason, Akt1 activity is compared based on kapp
= vo/[Akt1]. Samples from each reaction (5 µl) were spotted on P81 paper at
specified time points. Following washes with 1% phosphoric acid (3 × 10 min)
and 95% ethanol (1 × 5 min), the P81 paper was air-dried. Incorporation of 32P
into the substrate peptide was detected by exposing the P81 paper to a phosphorimaging screen. The 32P-peptide products were imaged and quantitated using a
Storm 860 Molecular Imager and ImageQuant TL software (GE Healthcare).

3.3.6 Kinase inhibition assay. A concentration gradient (0.001, 0.05, 0.5, 1, 5, 10
µM) of Akti-1/2 inhibitor VIII (Sellekchem, Houston, TX, USA) (22) was selected
to determine the concentration dependence of Akt1 inhibition. Kinase inhibition
assays were performed exactly as described above (section 3.3.5) and with the
addition of dimethyl sulfoxide at 10% (v/v) (control) or with the indicated
concentration of Akti-1/2 inhibitor. For each condition, initial velocity was
determined over a time course of 10 minutes with time points at 0, 2, 5 and 10
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min (Figure S3.3). In the inhibition assays, following established protocols (16),
the inhibitor was pre-incubated with the enzyme for 5 min at 37°C before
addition of ATP and Akt1 substrate peptide to start the reaction. The time
courses were used to determine the initial velocities of each reaction. The fraction
of enzyme inhibition was measured based on initial velocities of uninhibited and
inhibited reactions. From these data, half maximal inhibitory concentration (IC50)
values were calculated using Sigma Plot (Systat Software, Inc, San Jose, CA).

3.4 Results
3.4.1 Production of recombinant Akt1 variants. We recently established a
method to produce full length Akt1 variants with programmed phosphorylations
(11). Here we applied this method to produce site-specifically phosphorylated
Akt1 variants lacking the auto-inhibitory PH domain (ΔPH-Akt1). The approach
combines in vivo enzymatic phosphorylation with genetic code expansion to
produce Akt1 variants containing either or both pThr308 and pSer473 (Figure
3.2).
Using genetic code expansion (11,18), we incorporated pSer in response to
a UAG stop codon at position 473 in the relevant Akt1 constructs. Thr308 was
site-specifically phosphorylated by the co-expression of the upstream kinase
PDK1 in E. coli. We (11) and others (23) have demonstrated that PDK1 is strictly
specific in phosphorylating only the 308 site in Akt1. We used these methods in
isolation or in combination to produce the three physiologically relevant Akt1
variants pAkt1S473, pAkt1T308, and ppAkt1T308,S473 (Figure 3.2). We observed that the
ΔPH-Akt1 variants were all more soluble and were produced at 1.5 to 7-fold
greater yield per liter of E. coli culture than the corresponding full length Akt1
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variants (Table 3.1). As previously (11), we confirmed phosphorylation of the
Thr308 site (Figure 3.3C) and the Ser473 site (Figure S3.1) by mass spectrometry.

Table 3.1 Protein yields for Akt1 variants.
Protein Yields
(µg/L E. coli culture)
Akt1 variant
full length
ΔPH Akt1
Akt1 (unphosphorylated)
46
330
S473
pAkt1
100
150
pAkt1T308
37
235
T308,S473
ppAkt1
45
224

3.4.2 Recombinant Akt1 produced in E. coli versus Sf9 cells. Earlier work
established production of partially active and truncated Akt1 in E. coli, which
was unsuccessful in producing a sufficient amount of full length Akt1 to
determine activity (24). Although we recently overcame these difficulties and
developed a robust protocol to produce full length Akt1 from E. coli with
programmed phosphorylation, studies in the intervening period relied on insect
Sf9 cell culture to produce recombinant Akt1 (25). The ability to generate ppAkt1
from insect cells, however, requires a complex and low yield in vitro procedure
to phosphorylate Akt with 2 additional purified upstream kinases in the presence
of lipid vesicles (25). Protein production in Sf9 cells fails to produce Akt1 with
site-specific or programmed phosphorylation. The resulting protein is a mixture
of singly and doubly phosphorylated species (26).
In order to benchmark the activity of the recombinant phosphorylated
Akt1 protein we produce in E. coli, we compared the activity of full length
ppAkt1 to active Akt1 purchased from Abcam. The commercially available full-
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length Akt1 is made by a protocol similar to that established previously (25) in
which Akt1 protein production in Sf9 cells followed by in vitro phosphorylation
of the purified Akt1 with purified PDK1. In testing an initial lot of active Akt1
(lot 1), we found that the commercially available Akt1 enzyme was catalytically
deficient by a factor of 8-fold (Table 3.2) compared to the full length ppAkt1 we
produced (Figure 3.3A).

Table 3.2 Activity of Akt1 variants

Akt1 variant

Akt1 (unphosphorylated)
pAkt1S473
pAkt1T308
ppAkt1T308,S473
ΔPHAkt1 (unphosphorylated)
ΔPH pAkt1S473
ΔPH pAkt1T308
ΔPH ppAkt1T308,S473
Commercial Akt1
(abcam)
Lot 1
Lot 2

Akt1 Initial velocity
Apparent
amount
vo
catalytic rate kapp Activation Reference
(pmol)
(fmol/min)
(fmol/min/pmol (fold increase)
Akt1)
18

0.6 ± 0.2

0.03 ± 0.01

1.0 ± 0.3

[10]

18
1.8
1.8

46 ± 5
22 ± 4
79 ± 11

2.6 ± 0.3
12 ± 2
44 ± 6

85 ± 9
400 ± 70
1500 ± 200

[10]
[10]
[10]

18
18
0.18
0.18

1.4 ± 0.1
210 ± 20
370 ± 100
2300 ± 600

0.079 ± 0.006
12 ± 1
2100 ± 600
(13 ± 3) x 103

2.7 ± 0.2
390 ± 40
6900 ± 1800
(4 ± 1) x 105

this study
this study
this study
this study

18

100 ± 20

6±1

200 ± 30

this study

18

2200 ± 700

120 ± 40

4000 ± 1000

this study
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PRM-MS/MS was used to determine the identity of the residue at position
308 and the level of phosphorylation in ppAkt1 we produced and in the
purchased protein. Mass spectrometry revealed that the low activity of lot 1
enzyme was attributable to the low level of phosphorylation at position 308 (peak
intensity 1.3 × 101) and a relatively high level of un-phosphorylated Thr at
position 308 (Figure 3.3B). In contrast, ppAkt1T308,S473 that we produced showed a
high level (peak intensity 1.6 × 106) of Thr308 phosphorylation and unphosphorylated Thr308 was not detected (Figure 3.3C). We then purchased a
second lot of Akt1 enzyme (lot 2), and this enzyme displayed significantly more
but highly variable activity compared to lot 1 (Table 3.2). Presumably, the second
lot was quantitatively phosphorylated during production. In contrast to the
method we developed for pAkt1 production in E. coli (Figure 3.2), the protocol to
generate active Akt1 relying on Sf9 cells and subsequent in vitro phosphorylation
appears to lead to a variable level of phosphorylation and activity in the resulting
Akt1 preparations.
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Figure 3.3 Activity of full length ppAkt1 and commercially available active
Akt1. (A) Kinase activity assays over a 30-minute time course show substantially
reduced activity of commercial Akt1 (lot 1, green squares) compared to full
length ppAkt1 (blue diamonds) produced in E. coli. Commercial Akt1 lot 2 (red
circles) showed highly variable but similar activity to full length ppAkt1. (B)
Tryptic peptides from commercial Akt1 and ppAkt1 were analyzed by PRM-MS
analysis. The purchased ‘active’ Akt1 (lot 1) showed a low intensity peak for
phosphorylation at Thr308 (green peak at a retention time of ~40 min) and high
intensity peak for non-phosphorylated Thr308 (cyan peak, retention time of ~37
min). (C) PRM-MS analysis of ppAkt1T308,S473 showed a high intensity peak for
phosphorylation at Thr308 (green peak at a retention time of 40) and the nonphosphorylated Thr308 was undetectable.

3.4.3 Impact of PH domain deletion on differentially phosphorylated Akt1. In
order to determine the impact of the PH domain on each phospho-form of Akt1,
we next assayed the activity of specifically phosphorylated ΔPH-Akt1 variants
using γ-[32P]-ATP and a substrate peptide for Akt1 (CKRPRAASFAE) that was
derived from GSK-3β, a well-established Akt1 substrate (11,27). In kinase assay
conditions that we previously optimized (11) to measure a wide range of Akt1
activity, we determined the apparent catalytic rate of each ΔPH-Akt1 variant (un-
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phosphorylated, pAkt1S473, pAkt1T308, ppAkt1T308,S473). We then compared the
apparent catalytic rates to the measurements we had made previously with fulllength Akt1 and pAkt1 variants to ascertain the relative impact of each
phosphorylation state on the auto-inhibition by the PH domain.
As anticipated, all Akt1 variants lacking the PH domain were significantly
more

active

than

their

full-length

counterparts

(Table

3.1).

Doubly

phosphorylated ΔPH-Akt1 (ppAktT308,S473) showed the highest activity among all
three variants (Figure 3.3). The un-phosphorylated ΔPH-Akt1 showed a basal
level of activity that was significantly higher (2.7 ± 0.3 -fold) than the background
activity we recorded for full length un-phosphorylated Akt1 (Table 3.3).
Although both un-phosphorylated Akt1s would not be of sufficient activity to
induce Akt1-dependent signaling in cells (2,11), it is interesting to note that the
auto-inhibitory effect of the PH domain is indeed measurable in the increased
minimal activity of un-phosphorylated ΔPH-Akt1 (Figure 3.4B).

Table 3.3 Relative activity of full length versus ΔPH Akt1 variants
full
length
Akt1 variant
Akt1
Akt1 (un-phosphorylated) 1.0 ± 0.3
pAkt1S473
1.0 ± 0.1
T308
pAkt1
1.0 ± 0.2
ppAkt1T308,S473
1.0 ± 0.1

ΔPH
Akt1
2.7 ± 0.2
4.6 ± 0.4
175 ± 50
295 ± 68
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Figure 3.4 Enzyme activity of ΔPH-Akt1 variants. (A) The activity of
differentially phosphorylated ΔPH Akt1 variants with the GSK-3β substrate
peptide was measured over a 30-minute time course. Akt1 phosphorylated at
both 308 and 473 (ΔPH ppAktS473, T308, blue diamonds) showed maximal activity
compared to the un-phosphorylated ΔPH-Akt1 (gray circles), and singly
phosphorylated Akt1 variants: ΔPH pAkt1T308 (black cross) and ΔPH pAkt1S473
(pink diamonds). (B) The basal activity of un-phosphorylated ΔPH Akt1 (gray
circles) was compared to full length

Compared to un-phosphorylated ΔPH-Akt1, the most active doubly
phosphorylated Akt1 variant (ΔPH- ppAktT308,S473) showed 150,000-fold increase
in relative catalytic rate (Table 3.2, Figure 3.4). Since rapid enzyme kinetics were
observed with 18 pmol of enzyme with both these variants containing Thr308
phosphorylation, the enzyme concentrations were subsequently reduced by 10-
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fold and 100-fold to obtain a highly accurate initial velocity with which to
determine the apparent rate (kapp = vo/[enzyme]) (Figure S3.2).
Interestingly, dual phosphorylation of ΔPH-Akt1 leads to 100-fold greater
increases in activity than that observed upon dual phosphorylation of the fulllength enzyme, which is 1500-fold more active that the un-phosphorylated fulllength enzyme. The data indicate the PH domain significantly dampens the
catalytic activity endowed by phosphorylation at Thr308 and Ser473 (Figure 3.5).
The ΔPH-Akt1 variant with a single phosphorylation at Thr308 site was robustly
active, 2500-fold above the unphosphorylated ΔPH-Akt1, yet 60-fold reduced
activity compared to the doubly phosphorylated enzyme ΔPH-ppAktT308/S473
(Table 3.2). Phosphorylation at the C-terminal site Ser473 activated the enzyme
140-fold above the un-phosphorylated control, but to a lesser extent (18-fold)
than the ΔPH-pAkt1T308. We previously observed a quantitatively similar pattern
of activity with the full length Akt1 variants (Table 3.2, (11)).
We found that the PH domain exerts an auto-inhibitory effect, the strength of
which depends on the phosphorylation status of the Akt1 enzyme. We compared
the apparent catalytic rates (kapp) (Figure 3.5A) and normalized relative catalytic
rates (Figure 3.5B) between the full length (11) and PH domain deficient Akt1
variants. In the context of a single phosphorylation at Ser473, the PH domain is
associated with a ~5-fold reduction in activity (Table 3.3, Figure 3.5). In the singly
phosphorylated pAkt1T308 enzyme the auto-inhibition is far stronger (175-fold).
The two phosphorylations together led to a super-additive inhibitory effect (295fold) in the doubly phosphorylated enzyme (Figure 3.5).

105

A

100000

Series1
full length Akt1
10000

Series2
ΔPH-Akt1

log10(kapp)

1000

100

10

1

0.1

0.01
1
Akt1

B

pAkt12S473

pAkt13T308 ppAkt14T308,S473

1000

log10(normalized kapp)

Series1
full length Akt1

100

Series2
ΔPH-Akt1

10

1

0.1
1
Akt1

2
pAkt1S473

pAkt13T308 ppAkt14T308,S473

Figure 3.5 Impact of the PH domain on the activity of differentially
phosphorylated Akt1. (A) Apparent catalytic rates (kapp) and (B) normalized kapp
values of full-length Akt1 variants (blue) and ΔPH Akt1 variants (red) are shown.
Error bars represent 1 standard deviation of triplicate measurements.

We found that the PH domain exerts an auto-inhibitory effect, the strength of
which depends on the phosphorylation status of the Akt1 enzyme. We compared
the apparent catalytic rates (kapp) (Figure 3.5A) and normalized relative catalytic
rates (Figure 3.5B) between the full length (11) and PH domain deficient Akt1
variants. In the context of a single phosphorylation at Ser473, the PH domain is
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associated with a ~5-fold reduction in activity (Table 3.3, Figure 3.5). In the singly
phosphorylated pAkt1T308 enzyme the auto-inhibition is far stronger (175-fold).
The two phosphorylations together led to a super-additive inhibitory effect (295fold) in the doubly phosphorylated enzyme (Figure 3.5).

3.4.4 Chemical inhibition of phosphorylated Akt1 variants. Given the
differential impact of Akt1 phosphorylation on auto-inhibition, we next
identified phosphorylation dependence in the interaction between Akt1 and a
clinically relevant drug scaffold, Akti-1/2 inhibitor VIII. Several classes of
chemical inhibitors were developed to repress aberrant Akt1 activity in cancer
cells (28). Early Akt1 inhibitors focused on ATP competitive compounds (29), yet
these molecules suffered from significant cross reactivity with other AGC family
kinases (30). For this reason, subsequent efforts focused on allosteric Akt1
inhibitors. Akti-1/2 is an allosteric inhibitor that binds Akt1 in a cleft between the
kinase and PH domains, locking the enzyme in a non-catalytic confirmation
(Figure 3.6). Biochemical data with different Akt1 preparations have provided
estimates of IC50 of Akt1 for the Akti-1/2 inhibitor ranging from 58 nM to 2.7 µM
(22,31,32) (Table 3.4). We suspected that this range of values result from
preparations of Akt1 with various levels of phosphorylation with less active Akt1
preparations leading to an underestimate of IC50. In addition, previous studies
were unable to isolate the contribution of each regulatory phosphorylation site to
inhibition by Akti-1/2.
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Figure 3.6 Structure of Akt1 in active and inhibitor bound forms. (A) The
structure of DPH-pAkt1Thr308 Ser473Asp (PDB 1O6K (33)) is shown in complex
with ATP analog (AMP-PNP) and substrate peptide (purple). (B) Structure of the
full length Akt1 (un-phosphorylated) is shown in complex with the Akti-1/2
inhibitor VIII (PDB 1O96 (34)) binding in the cleft between the kinase domain
(green) and the N-terminal PH domain (red).

Table 3.4 Akti-1/2 inhibitor half maximal inhibitory concentration (IC50) for
pAkt1 variants
Akt1 variant
ppAkt1T308,S473
pAkt1T308
pAkt1S473
active
active
active
active

inhibitor type
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor VIII
Akti-1/2 inhibitor
Akti-1 inhibitor

IC50 (µM)
1.2 ± 0.3
0.3 ± 0.1
1.3 ± 0.1
0.058
0.1
2.7
4.6

expression system
E. coli
E. coli
E. coli
Drosophila S2 cells
HEK 293 cells
Drosophila S2 cells
Drosophila S2 cells

reference
this study
this study
this study
[22]
[31]
[32]
[32]
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We conducted Akt1 inhibition assays using Akti-1/2 concentrations
varying from 0.01 to 10 µM. All three full-length phosphorylated Akt1 variants
showed concentration responsive enzyme inhibition (Figures 3.7, S3.3-S3.6). Akti1/2 was most potent (IC50 = 300 nM) when only the Thr308 site was
phosphorylated (Table 3.4). Interestingly, at the lower concentrations of Akti-1/2
(0.001, 0.05, 0.5 µM) the compound was not effective in inhibiting the activity of
pAkt1S473. Akt1 phosphorylated at the C-terminal Ser473 site was overall more
resistant to inhibitor VIII inhibition resulting an IC50 value of 1.3 µM. In a
surprising finding, the doubly phosphorylated enzyme had an indistinguishable
IC50 from the pAkt1S473 enzyme. Together the data indicate that Ser473
phosphorylation provides a 4-fold increase in resistance to the Akti-1/2 inhibitor
even in the presence of phosphorylation at Thr308. This is the first report that
demonstrating phosphorylation dependence in the interaction between Akt1 and
an inhibitor.
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Figure 3.7 Chemical inhibition of full length phosphorylated Akt1 variants. (A)
Inhibition of (A) pAkt1S473, (B) pAkt1T308, and (C) ppAkt1T308,S473 with varying
concentrations (0.001, 0.05, 0.5, 1, 5, 10 µM) of Akti-1/2 inhibitor VIII. The
resulting IC50 values are in Table 3.4.
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3.5 Discussion
Akt1 is a prime target for therapeutic intervention due to its involvement in
regulating a multitude of cellular pathways (35,36). Aberrant Akt function has
been linked to cancers and a variety of human diseases related to metabolic
regulation, immune function, and neurological development (2). The broad range
of cellular processes governed by Akt, therefore, presents an opportunity for
single-target therapeutic intervention of a variety of conditions. To capitalize on
this opportunity, compounds that selectively attenuate Akt1 activity rather than
global kinase inactivation are required. This need is reflected in clinical trials
which show that non-specific Akt inhibition in cancer therapy, due to inadvertent
off-targeting of closely related kinases or multiple Akt isozymes, can result in
detrimental side-effects including liver damage and metabolic disorders (37-40).
Accordingly, the development of small molecule inhibitors for Akt has reflected
this sentiment towards engineering greater target specificity (28). From the
earliest ATP-competitive inhibitors that unintentionally inhibited related AGC
kinases, to more recent allosteric inhibitors that preferentially target Akt or even
a subset of Akt isozymes, the continued pursuit for Akt1 inhibitor specificity
requires an expanded understanding of the molecular basis of Akt1 activation
and inhibition.
Previous work was unable to uncover the role of each regulatory site (Thr308
and Ser473) in the inhibition kinetics of Akt1. Given this critical knowledge gap,
we investigated the role of Akt1 phosphorylation status on the auto-inhibitory
effect of the PH-domain and on allosteric inhibition by Akti-1/2.
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3.5.1 Phosphorylation-Dependent Auto-Inhibition of Akt1. The N-terminal PH
domain is shared amongst all three Akt isozymes and its direct function is to
mediate protein-lipid interactions. It is well documented that the PH domain
binding to a lipid second messenger PIP3 in cell membranes releases the
inhibitory effect of the PH domain (2). Here, we produced differentially
phosphorylated Akt1 variants with and without the PH domain in E. coli using
genetic code expansion to incorporate pSer473 and the upstream Thr308 kinase
PDK1 was co-expressed in E. coli, leading to quantitative phosphorylation of the
recombinant

Akt1

protein.

Compared

to

un-phosphorylated

Akt1,

all

phosphorylated variants showed increased enzyme activity.
Previously, live cell imaging studies revealed that once phosphorylated, Akt1
favors a ‘PH-out’ confirmation that increases Akt1 activity in the downstream
phosphorylation of substrate proteins both in the cytoplasm and nucleus. In
addition, binding of Akt1 to PIP3 in the plasma membrane further releases the
auto-inhibitory effect of the PH domain (41,42). Although phosphorylation of the
kinase domain at Thr308 is known to reduce the PH domain’s affinity towards
the kinase domain (41), the contribution of Thr308 and Ser473 phosphorylation to
auto-inhibition by the PH domain was unknown.
We quantitated the release of PH domain mediated inhibition corresponding
to each phosphorylation site and both sites in combination. Our data revealed
that the magnitude of the auto-inhibitory effect of the PH domain was sensitively
dependent on the phosphorylation status of Akt1. In comparison to the activity of
full length Akt1 phospho-variants, deletion of the PH domain significantly
increased activity. In comparison to singly phosphorylated Akt1 variants, the
auto-inhibitory effect of the PH domain was strongest (295-fold) in the most
active and doubly phosphorylated Akt1 variant. Interestingly, the doubly
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phosphorylated Akt1 displayed an increase in activity upon PH domain deletion
that was greater than the sum of the effects observed for the singly
phosphorylated Akt1 variants. The data suggest a novel finding that the PH
domain dampens the activity of Akt1 variants in a phosphorylation-dependent
manner.
The combination of phosphorylation and PH domain release regulate the
kinase activity of Akt1 over a 400,000-fold range. The data indicate the degree to
which the un-phosphorylated PH-in conformation of Akt1 is suppressed in
comparison to the PH-out doubly phosphorylated version of the enzyme that
exists at the plasma membrane in living cells. Recent in vitro biochemical work
suggested that association with PIP3 containing lipid vesicles stimulated the
activity of a full length Akt1 protein by 7-fold (42). The authors suggested that
this may be an underestimate due to low levels of phosphorylation (10% Thr308,
1% Ser473) in their Akt1 prepared from Sf9 cells. Our data suggest release of the
PH domain in the context of doubly phosphorylated Akt1 would lead to maximal
activity increase of 300-fold; a PH domain dependent reduction of less than this
value would indicate there may be significant interaction between the Akt1
kinase and PH domains even in the PIP3 bound state at the plasma membrane.
Indeed a recent debate in the literature (43) is underway to explain how Akt1
activity can be maintained far from the membrane. Recent findings suggest that
Akt1 is de-phosphorylated on a time scale of ~10 minutes following dissociation
from PIP3 on the plasma membrane (44). Multiple nuclear substrates of Akt1 are
known to be phosphorylated much more rapidly, on a time scale of seconds (45).
Although the authors suggested that all or perhaps most of the active Akt1 is
membrane-associated (44), this finding disputes several independent studies
identifying

many

cytosolic

and

nuclear

targets

of

Akt1-dependent
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phosphorylation. Multiple studies clearly identified both phospho-Akt1, e.g., (4547), and directly measured Akt1 activity in the nucleus (10). Using a fluorescent
reporter that quantifies Akt1 activity in live cells in real time, Kunkel and
Newton observed Akt1 activity distributed in both the cytoplasm and nucleus on
a time scale of seconds to minutes following growth factor stimulation. Their
data further show similar levels of Akt1 activity in the nucleus and cytoplasm,
with a delay in the peak activity in the nucleus of ~2 minutes. Additional
experiments confirmed this lag is related to the time it takes for active Akt1 to
translocate from the plasma membrane to the nucleus (10). In light of our data
and these findings, the membrane associated Akt1 is likely significantly more
active than doubly phosphorylated Akt1 found in the nucleus and cytosol.
Phosphorylated Akt1, nevertheless, does persist away from the membrane,
retaining significant activity in comparison to the un-phosphorylated Akt1.

3.5.2

Phosphorylation-Dependent

Chemical

Inhibition

of

Akt1.

Post-

translational-modifications, of which phosphorylation is the most common, are a
ubiquitous mechanism that cells use to tune the activity of individual proteins
and increase the functional diversity of the proteome. Phosphorylation can have
a significant impact on the activity of proteins, kinases are a prime example, and
phosphorylation status of a protein target can accordingly impact the ability of
small molecules to inhibit enzyme activity. In the experiments presented here, we
determined precisely how the phosphorylation-status of Akt1 influences the
repression of kinase activity by chemical inhibition. We investigated the Aktspecific allosteric inhibitor Akti-1/2. Based on the results of our assays, the
phosphorylation status of Akt1 can indeed influence the degree to which Akti-1/2
is able to act on Akt1. Akti-1/2 was most effective at inhibiting pAkt1T308, whereas
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phosphorylation at position Ser473 in either pAktS473 or ppAktT308/S473, reduced the
relative effectiveness of the inhibitor by a factor of 4.
Ser473 phosphorylation appears to act as a built-in mechanism of drug
resistance for Akt1. It is well established that hyper-phosphorylation of Akt1 at
both regulatory sites is linked to poor prognoses and therapeutic resistance (36,48). The accepted model for Akti-1/2 activity suggests that the compound locks
Akt1 into the auto-inhibited or PH-in confirmation and prevents Akt1 from
binding PIP3 in the plasma membrane, inhibiting phosphorylation at Thr308 and
Ser473 (49). Our data also suggest that although limited by Ser473
phosphorylation, the Akti-1/2 has significant activity in inhibiting the prephosphorylated Akt1 variants that the inhibitor initially encounters in the cell.
Studies in cell culture and mouse models show that the short-term impact of
Akti-1/2 treatment is that pThr308 and pSer473 levels are depleted within hours.
A related allosteric Akt inhibitor, and the most clinically promising (50)
compound, MK-2206 significantly reduces Ser473 phosphorylation after 10 hours
in mouse models with patient derived xenografts of endometrial tumors (51).
Surprisingly, breast cancer cells (BT474) treated with Akti-1/2 (1 µM) showed
a rebound effect in Akt1 phosphorylation status following Akti-1/2 treatment.
These cells have amplified HER2 genes and constitutively activate the PI3K/Akt
signaling cascade. In short term experiments (minutes to hours), Akt1
phosphorylation reduces in response to inhibitor treatment, but at longer times
(2-3 days) Akt1 phosphorylation status returns to stimulated levels in these
cancer cells. In this longer time frame, phosphorylation of downstream Akt1
target, S6K, was not restored, but PRAS40 phosphorylation was partially restored
concomitant with increased Akt1 phospho-status. The study provided evidence
that Akti-1/2 ultimately induces the expression and activation of receptor
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tyrosine kinases EGFR, HER3, and HER4, which in turn re-activate Akt1 (52).
Interestingly, in mouse models a similar rebound in Ser473 phosphorylation
following treatment with MK-2206 was observed on time courses of 5 to 20 days
(53). In these cases, Ser473 phosphorylation may provide the tumor cell with a
means to reduce the effectiveness of Akt1 inhibitor. The data suggest the need to
develop an inhibitor that is more effective towards the most active and doubly
phosphorylated form of Akt1.

3.5.3 Synthetic Biology Approach to Generate Active Akt1. In our current study,
and previous work (11,17-19), we demonstrated that genetic code expansion with
pSer in E. coli provides a simple route to produce designer phosphoproteins.
Here, we have produced differentially phosphorylated Akt1 variants with and
without the PH domain in E. coli using genetic code expansion and enzymatic
phosphorylation in E. coli. We found that the variants lacking the PH domain
were produced at significantly higher yield compared to the full length Akt1
protein. The ability to produce recombinant Akt1 protein with programmed
phosphorylation(s) was essential for our investigations in the role of each
phospho-site in Akt1 inhibition.
In comparison with our previous work (11), we found the system we
developed to produce Akt1 with either or both regulatory phosphorylation sites
(Figure 3.2) leads to a consistently active Akt1 variant with indistinguishable
batch to batch variability. This is in contrast to the commercially available Akt1
produced in using Sf9 cell system followed by in vitro PDK1 phosphorylation of
Thr308 (25). We observed a vast batch-to-batch variability of enzyme activity in
the commercially available Akt1, which warrants cautious attention in its
experimental use. Previous work also established that Akt1 produced in Sf9 cells
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leads to a mixture of singly and doubly phosphorylated Akt1 variants (26) at
times leading to a low stoichiometry of phosphorylation (42) (Figure 3.3B). Our
approach consistently results in site-specifically phosphorylated and active Akt1
variants that provide a reliable and consistent source of protein that for
biochemical studies and applications in inhibitor screening.

Acknowledgements: We are grateful to Ilka Heinemann and Shawn Li for
critical discussions and suggestions.
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3.7 Supporting information:
3.7.1 Supporting experimental procedures
Affinity column chromatography. The His-tagged proteins were purified using
Ni affinity column chromatography. 0.5 ml of Ni-NTA resin (Thermo-Fisher
Scientific) was used for 1 l of E. coli culture. The cell lysates (see Methods) were
loaded into the column (2 ml column volume) and washed with 20 column
volumes of wash buffer A (20 mM Hepes, 150 mM NaCl, 3 mM βmercaptoethanol, 3mM Dithiothreitol, 1 mM Na3VO4 and 5 mM NaF, 15 mM
imidazole) followed by 10 column volumes of wash buffer B (20 mM Hepes, 150
mM NaCl, 3 mM β-mercaptoethanol, 3mM DTT, 1 mM Na3VO4 and 5 mM NaF,
20 mM imidazole). Protein was eluted using an elution buffer (20 mM Hepes, 150
mM NaCl, 3 mM β-mercaptoethanol, 3mM dithiothreitol, 1 mM Na3VO4 and 5
mM NaF) with 75 mM Imidazole. The same protocol was used for Akt1 variants
with phosphomimetic mutations except: 1) phosphatase inhibitors were excluded
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from the buffers, 2) the imidazole concentrations of the wash buffers were 20 - 50
mM, and 3) the imidazole concentration of the elution buffer was 200 mM.
Fractions were run on 10% SDS (sodium dodecyl sulfate) poly-acrylamide gels.
As detailed previously [1], Akt1 variants were further purified by size exclusion
chromatography.

3.7.2 Supporting References
1.

2.

Balasuriya, N.; Kunkel, M.T.; Liu, X.; Biggar, K.K.; Li, S.S.; Newton, A.C.;
O'Donoghue, P. (2018) Genetic code expansion and live cell imaging reveal
that thr308 phosphorylation is irreplaceable and sufficient for akt1 activity.
J Biol Chem, 293, 10744-10756
George, S.; Aguirre, J.D.; Spratt, D.E.; Bi, Y.; Jeffery, M.; Shaw, G.S.;
O'Donoghue, P. (2016) Generation of phospho-ubiquitin variants by
orthogonal translation reveals codon skipping. FEBS Lett, 590, 1530-1542

3.7.3 Supporting Tables
Supplementary Table S3.1 Plasmids used in this study
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Plasmid ID

Plasmid
backbone

Selectable
marker

Inserted
genes

Genetic
modifications

Protein product

(1) WT Akt1

pDS0 (pUC)
[2]

Amp

AKT1

None.

Akt1, unphosphorylated.
(full-length, inactive) [1]

(2) WT Akt1PDK1

pCDF-Duet-1

Strep

AKT1
PDK1

None.

(3) Akt1
UAG473

pCDF-Duet-1

Strep

AKT1

UAG mutation at
position 473 in
AKT1.

(4) Akt1-UAG473- pCDF-Duet-1
PDK1

Strep

AKT1
PDK1

UAG mutation at
position 473 in
AKT1.

(5) pSer-OTS

Kan

tRNAsep
(5x)
SepRS9
EFSep21

(6) ΔPH-WT Akt1 pDS0 (pUC)
[2]

Amp

AKT1

Akt1, phosphorylated at
position T308.
(full-length, active) [1]
Akt1, phosphorylated at
position S473.
(full-length, slightly
active) [1]
Akt1, phosphorylated at
positions T308 and S472.
(full-length, highly
active) [1]
pSer orthogonal
translation system,
capable of decoding
UAG codons and
incorporating pSer into
nascent peptides [2]
ΔPH-Akt1,
unphosphorylated.
(truncated, inactive)

(7) ΔPH-WT Akt1- pCDF-Duet-1
PDK1

Strep

AKT1
PDK1

(8) ΔPH-Akt1UAG473

pCDF-Duet-1

Strep

AKT1

(9) ΔPH-Akt1
UAG473-PDK1

pCDF-Duet-1

Strep

AKT1
PDK1

pDS-pSer2

This system is
comprised of the
2nd generation
mutants of the
pSer incorporation
system.
Deletion of the PH
domain from AKT1
(Δ residues 2-109).

Deletion of the PH ΔPH-Akt1,
domain from AKT1 phosphorylated at
(Δ residues 2-109). position T308.
(truncated, active)
Deletion of the PH ΔPH-Akt1,
domain from AKT1 phosphorylated at
(Δ residues 2-109). position S473.
UAG mutation at (truncated, slightly
position 473 in
active)
AKT1
Deletion of the PH ΔPH-Akt1,
domain from AKT1 phosphorylated at
(Δ residues 2-109). positions T308 and S472.
UAG mutation at (truncated, highly active)
position 473 in
AKT1.
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3.7.4 Supporting Figures
RPHFPQFpSYSASGTAL
1845.8923

% Intensity

1846.8923

1847.8923

1848.8923

Mass (m/z)

Figure
Mass
spectra
confirming
genetically
encoded phosphoserine
in ΔPH-pAkt1.in
FigureS1.
S3.1
Mass
spectra
confirming
genetically
encoded phosphoserine
Tryptic digested peptides of ΔPH-ppAkt1T308, S473 were subjected to MALDI-TOFF mass
T308,S473
ΔPH-ppAkt1.
Tryptic
digestedpeptide
peptides
of ΔPH-ppAkt1
were subjected to
spec
analysis and
the C-terminal
of ΔPH-Akt1
carrying a single
phosphorylation was detected.

MALDI-TOF mass spectrometry The C-terminal peptide of ΔPH-Akt1 carrying a
single phosphorylation was readily detected. The isotopic masses of the peptide
carrying the most abundant peak of

12

C isotope (observed m/z = 1845.8923;

expected m/z = 1845.8378) and the 3 consecutive peaks with 13C isotopes (m/z =
1846.8923, 1847.8923, 1848.8923, respectively) are shown.
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Figure S3.2 Initial velocity measurements for highly active ΔPH Akt1 variants.
(A) ΔPH-ppAkt1T308, S473 and (B) ΔPH-pAkt1T308 were diluted by 10-fold and 100fold, respectively, to obtain a linear range of increasing enzyme activity. Initial
velocities were calculated using the data points at the linear range of 100-fold
diluted enzyme.
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0.5 μM Akti1/2
T308
1 μM Akti1/2 + pAkt1

8
6
4

5 μM Akti1/2
10 μM Akti1/2

2
0
0

5

10

C

p-peptide (pmol)

time (min)

pAkt1S473
DMSO + pAkt1S473
0.001 μM Akti1/2
0.05 μM Akti1/2
0.5 μM Akti1/2

1.5
1

1 μM Akti1/2
+ pAkt1S473

0.5
5 μM Akti1/2
10 μM Akti1/2

0
0

5

10

time (min)

Figure S2: Enzyme inhibition curves of the full length Akt1 variants incubated
Figure S3.3 Inhibition
of the full length Akt1 variants incubated with Akti-1/2
pAktT308, (3) pAkt1S473 variants were incubated with increasing concentrations (0.00
T308Different colors
monitored
over aT308,
10 S473
min, time
period.
inhibitor VIII.
(A) ppAkt1
(B) pAkt
, (3) pAkt1S473represent
variants different
were concentrati

incubated with increasing concentrations (0.001 uM to 10 uM) of Akti1/2. Error
bars indicate 1 standard deviation based on triplicate experiments.
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Figure S3: Autoradiographs of Akt1 inhibitor assays with ppAkt1T308, S473 variants. Time co
S473
T308,S473
Figure
S3.4
Autoradiographs
of Akt1 inhibitor
assaysAkti1/2.
with ppAkt1
.performed
Time
with varying concentrations
of inhibitor
AssaysT308,
were
in triplica
ppAkt1
C1 without substrate peptide, C2 without enzyme, C3 only kinase assay buffer.
courses are shown for the reaction catalyzed by ppAkt1T308,S473 with the indicated

concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as
indicated by R1-R3). Controls include: C1 without substrate peptide, C2 without
enzyme, C3 only kinase assay buffer.
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Figure S4: Autoradiographs of Akt1 inhibitor assays with pAkt1T308 variant. Time cour
T308
FigurebyS3.5
Autoradiographs
of Akt1 inhibitor
assaysAkti1/2.
with pAkt1
. Time
T308 with varying concentrations
of inhibitor
Assays were
performed in tripl
pAkt1
include: C1 without substrate peptide, C2 without enzyme, C3 only kinase assay buffer.
courses are shown for the reaction catalyzed by pAkt1T308 with the indicated

concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as
indicated by R1-R3). Controls include: C1 without substrate peptide, C2 without
enzyme, C3 only kinase assay buffer.

128
R1

R2

R3

pAkt1S473

R1
DMSO

R2

5 μM

0.5 μM

0.05 μM

10 min

2 min

0.001 μM

5 min

2 min

R3

R1 R2
0.001 μM

R3
C1

2 min

C
2

5 min
10 min
2 min

1 μM

C3

5 min
10 min

5 min
10 min

S473
FigureFigure
S3.6 Autoradiographs
of Akt1
inhibitor
. variants.
Time
S5: Autoradiographs
of Akt1
inhibitorassays
assayswith
withpAkt1
pAkt1S473
Time cou
Assays
were
performed
in
triplicate
pAkt1S473 with varying concentrations of inhibitor Akti1/2.
S473
courses
are
shown
for
the
reaction
catalyzed
by
pAkt1
with
the
indicated
without substrate peptide, C2 without enzyme, C3 only kinase assay buffer.

concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as
indicated by R1-R3). Controls include: C1 without substrate peptide, C2 without
enzyme, C3 only kinase assay buffer.
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Chapter 4

4 Phosphorylation-dependent substrate selectivity of Akt1

4.1 Abstract
Protein kinase B (Akt1) is a central node in a signaling pathway that regulates cell
survival. The diverse pathways regulated by Akt1 are communicated in the cell
via the phosphorylation of perhaps as many as ~100 different cellular substrates.
Akt1 is itself activated by phosphorylation at Thr308 and Ser473. We recently
developed a method to produce Akt1 with programmed phosphorylation at either
or both key regulatory sites. This breakthrough previously enabled resolution of
the contribution of each phospho-site to the activation of Akt1. Here we used both
defined and randomized peptide libraries to map the substrate selectivity of singly
and doubly phosphorylated Akt1 variants. To globally quantitate Akt1 substrate
preferences we synthesized two Akt1 substrate peptide libraries: one based on 84
“known” substrates and a larger oriented peptide array library (OPAL) of 1011
peptides. The data revealed that each phospho-form of Akt1 has distinct substrate
requirements. Surprisingly, phosphorylation of Ser473 in the context of a pAkt1T308
enzyme led to increased activity on some, but not all Akt1 substrates. This is the
first report that Ser473 phosphorylation does not simply increase Akt1 kinase
activity, rather we found that phosphorylation at Ser473 modulates global
substrate preferences by selectively increasing, decreasing or not altering activity
compared to the kinase singly phosphorylated at Thr308. We also verified a new
Akt1 target as the terminal nucleotidyltransferase (germline development 2) Gld2.
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Our data show that Akt1 site-specifically phosphorylates Gld2 at Ser116. Together
these data suggest new and expanded roles for Akt1 signaling in regulating
cellular processes.

4.2 Introduction
Protein kinase B (PKB, Akt1) is a central node in the Phosphoinositide 3kinase (PI3K)/Akt signaling pathway that regulates cell survival. There are three
isozymes of Akt (Akt1, Akt2, Akt3) identified in mammalian cells (1) with both
distinct and overlapping roles. Akt1 is an oncogenic kinase that is overactive and
hyper-phosphorylated in most cancers and a prime target in cancer therapy (2).
Although direct Akt1 inhibitors have not been generally successful as
monotherapies (3), Akt1 inhibitors show promise in combination with, e.g.,
mitogen-activated protein kinase inhibitors (4). Activated Akt1 phosphorylates
downstream targets that regulate many cellular processes including cell survival
and apoptosis (5). The diverse cellular functions of Akt1 are mediated by its ability
to phosphorylate perhaps as many as hundreds of cellular substrates, although the
precise number is not known. Based on a large number of reports from the
literature, a catalog of ~200 known Akt substrates have been reported (6).
At present it is unclear if all of these substrates are truly phosphorylated by
Akt1 or to what extent these substrates are differentially phosphorylated by active
Akt1. Because the downstream phosphorylation profile of active Akt1 determines
which cellular programs are turned on or off by the enzyme, the ability to identify
novel Akt1 substrates will have significant impact on target selection and drug
discovery in Akt1 mediated chronic diseases such as cancer (1) and diabetes (7).
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We recently developed an approach to produce Akt1 variants with sitespecific phosphorylation at either or both key regulatory sites (8,9). Here we show
the method provides an indispensable tool for identifying the role of Akt1
phosphorylation status in substrate selectivity. The substrate selectivity associated
with specific Akt1 phospho-forms is challenging to resolve in the complex
environment of the cells (10). The phosphorylation status of Akt1 substrates
depend on many factors including the expression level and cellular localization of
Akt1 substrates as well as the off-rate of phosphate on these substrates as a result
of phosphatase activity (11). However, there remains a lack of understanding
regarding how the two key activating phosphorylation sites on Akt1 lead to
differences in substrate selection and downstream substrate phosphorylation (10).
The minimal Akt substrate recognition motif is R-5 X-4 R-3 X-2 X-1 S/T0 ϕ+1. X
represents any amino acid except Thr, Cys; ϕ represents a bulky hydrophobic
residue (Phe, Tyr etc.) and the phospho-accepting site is a Ser or Thr residue (12).
This motif was further validated through oriented peptide array library (OPAL)
screens where the -5 position was Arg and specific amino acids were designated
to -1, -2, +1 and +2 positions (13). The Akt target consensus was initially determined
using the amino acid sequences surrounding the phosphorylation site of the first
reported Akt substrate: glycogen synthase kinase 3 (GSK-3 ) (12). Arg residues at
position -3 and -5 were found to be specific to Akt whereas other AGC family
kinases such as the S6 kinase (S6K1), prefer Lys at -3 and -5 positions (10). Peptide
library screening is a gold standard method that has been widely used to
determine specific amino acid preferences of the kinase substrate recognition
motif. Degenerate peptide libraries or OPAL screens provide a systematic
approach to identify the important residues surrounding the phosphorylation site
on the substrate (13,14).

132
Here we synthetized designed and randomized (OPAL) peptide libraries to
define the substrate requirements for differentially phosphorylated Akt1 variants.
We discovered that the phosphorylation status of Akt1 has a significant impact on
substrate selectivity and on the specific residue preferences at each location in the
consensus motif. Akt1 kinase activity data over the OPAL library was used to
generate a score matrix that we used to rank putative novel Akt1 targets in the
human proteome. We validated one of these predicted Akt1 targets, the terminal
nucleotidyl transferase Gld2 (15).

4.3 Materials and Methods

4.3.1 Bacterial strains and plasmids. A codon optimized human AKT1 gene
lacking the PH domain was synthesize at ATUM (Newark, California, USA) and
sub-cloned (NcoI/NotI) into an isopropyl β-D-1-thiogalactopyranoside (IPTG)
inducible T7lac promoter driven pCDF-Duet vector with CloDF13-derived CDF
replicon and streptomycin/spectinomycin resistance (pCDF-Duet1-ΔPHAkt1). The
human PDPK1 gene, which was acquired from the Harvard PlasmidID repository
service (HsCD00001584, Boston, MA, USA), was sub-cloned (KpnI/NdeI) into the
second multiple cloning site of pCDFDuet-1. The codon for the residue in AKT1 at
position Ser473 was mutated to the amber (TAG) codon in the synthetic gene from
ATUM. Successful cloning was verified by DNA sequencing (London Regional
Genomics Centre, London, ON, Canada and Genewiz, Cambridge, MA, USA).

4.3.2 Protein and phosphoprotein production. Un-phosphorylated and
phosphorylated forms of Akt1 (pAkt1S473, pAkt1T308, ppAkt1T308,S473) were produced
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according to previously described methods (8,16) (See also the methods and SI
sections Chapters 2 and 3).

4.3.3 Library of known Akt1 substrate peptides. Based on reports from the
literature collated at the Phosphosite database (6), we selected 84 different peptides
to generate a library of ‘known’ Akt1 substrates. The substrate motifs derived from
these Akt1 substrates were synthesized in the following form: biotin-AX-6-XS /T0X1-X6YRR. The phosphorylation site (Ser or Thr) is located at the 0 position.

1 0

Each individual in-solution peptide was synthesized according to previously
reported methods (17).

4.3.4 Alanine scanning. In my previous studies of Akt1 (8,12) (Chapters 2-3), the
GSK-3β substrate peptide was used to assay a wide variety of phosphorylated
Akt1 variants. To identify critical residues for the activity of each Akt1 phospho-variant, a series of 12 GSK-3β derived peptides were synthesized with one of the
positions substituted to alanine. The in-solution peptides were synthesized
according to previously reported methods (17).

4.3.5 OPAL Akt1 activity screen. An oriented peptide library was designed as a
series of soluble library pools according to previously reported methods (14). The
known consensus sequence of Akt1 phosphorylation, which is biotin-AGGX-6X-5X4

R-3X-2X-1S0X1X2X3, was used as the design for library synthesis. X represents any

amino acid other than Ser, Thr or Cys. The phosphorylatable residues (Ser, Thr)
were excluded from the screen to avoid false positive signals when probing
position S0. Each of the 17 other canonical amino acids are tested in X positions.
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The -3 and 0 positions were fixed to Arg and Ser, respectively, where 0 position is
the phosphorylation site and R-3 is essential for substrate phosphorylation by Akt1
(12). In each of 128 distinct sub-library pools, one of the X positions was fixed to
one specific amino acid and every other X position was randomized. The total
library contains 1011 peptides.

4.3.6 Sequence Logos and database searching. Sequence logos of substrates
corresponding to each Akt1 variant were generated using WebLogo version 2.8.2
(18) or Seq2Logo 2.0 (19) as indicated. Using the data in Figure 4.1, we generated
an alignment of known peptides in which the population of each peptide was
linearly related to its activity level. The resulting peptide alignment was, thus,
most populated by the highest active peptides and least populated by the low
active peptides. This allow us to convert the activity data over known peptides
using WebLogo (Figure 4.3).
Using the OPAL data we generated position-specific scoring matrices
(PSSMs) according to a similar method used in Scansite (20). For each data set, a
selectivity matrix was calculated by dividing all activity values by the average
value for the complete array, i.e, a selectivity factor. A scoring matrix was
computed as the natural log of the selectivity matrix. Finally, the raw scoring
matrices were scaled by a factor of 10 multiplied by the selectivity factor for each
data set. The resulting PSSMs based on each OPAL data set were used to produce
sequence logos with the program Seg2Logo 2.0 (19). The PSSM-Logo was
computed using default values.
As an alternate approach to generate a PSSM, we also converted the OPAL
activity data to a set of Z-score matrices as before (21). The preference rank of each
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substrate was statistically determined and assigned a z score. The formula is given
below.

𝑋𝑖 − 𝑋′
𝑆
Xi= activity value of ith peptide sub-library, X’= mean activity over entire peptide
𝑍𝑖 𝑠𝑐𝑜𝑟𝑒 =

library, S=standard deviation of activity over entire peptide library.

The known human phospho-proteome was scored based on the amino acid
preferences at each position in the z-score PSSM. The sum z-scores at each position
in the target peptide was used to rank all peptides covering the human proteome.

4.3.7 NIH 3T3 cell culture. NIH 3T3 cells were purchased from American type
culture collection (CRL-1658), Manassas, VA, USA. Cells were grown at 37°C with
5% CO2 in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 4
mM L-glutamine, 4.5 g/L glucose, 1 mM sodium pyruvate, 1.5 g/L sodium
bicarbonate (Wisenet, 319-007-CL), 1% pen-strep solution (Fisher Scientific,
15140122) and bovine calf serum (ATCC, 30-2030). Cells were grown until 80%
confluence and passaged. Cells grown to 3 passages were used for the kinase
assays. Cells were harvested with 0.25% (v/v) trypsin-ethylenediaminetetraacetic
acid (EDTA) and incubated with cell lysis buffer (50 mM Tris-HCl, 1% Triton-100,
150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS) pH 7.5) for 5 min on ice. 200 µL
of lysis buffer was added per well of a 6-well plate. Cell lysate was centrifuged at
38000 ´ g at 4 °C for 10 min. Supernatants were transferred to sterile microcentrifuge tubes and lysate protein concentrations were determined using a
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Bradford assay according to manufacturer’s instructions (Bio-Rad Laboratories,
CA, USA).

4.3.8 Kinase assay for peptide libraries. Kinase assays with peptides or peptide
sub-libraries in dimethyl sulfoxide (DMSO) solution were conducted using
radiolabeled γ-[32P]-ATP according to previously reported methods (8) with slight
modifications as following: Akt1 activity was determined using 400 µM substrate
peptide for the known substrate library. The substrate concentration for the OPAL
library was 1 mM. 0.3 ng of kinase was incorporated per reaction. Each assay was
conducted in triplicate.

4.3.9 Kinase assay with NIH 3T3 cell extracts. The NIH 3T3 cell extracts in lysis
buffer were dialyzed into ATP free kinase assay buffer (25 mM 3-(Nmorpholino)propanesulfonic

acid

(MOPS)

pH

7.0,

12.5

mM

β-

glyceraldehydephosphate, 25 mM MgCl2, 5 mM ethylene glycol-bis(β-aminoethyl
ether-N,N,N’,N’-tetraacetic acid (EGTA), 2 mM EDTA) using an Amicon ultral-0.5
ml centrifugal device. Cellular proteins (18 µg) from the lysates were incubated
with 0.1 µg of the indicated Akt1 enzyme variant in 30 µL kinase assay buffer
containing 0.2 mM unlabeled ATP and 33 nM γ-[32P]-ATP. 10 µL from each
reaction were taken at 20 min and 80 min time points and boiled for 10 min in 3X
SDS loading dye (1 M Tris-HCl pH 6.8, 0.38 g/mL sucrose, 0.1 % bromophenol blue,
20% SDS, 3% (V/V) β-mercaptoethanol) and boiled for 10 min. Samples were
rissolved on a 10% polyacrylamide SDS gel, wrapped in plastic wrap, and placed
on a Whatman paper, and wrapped in Ceran wrap. The gel was exposed to a
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phosphorimaging

screen

overnight

at

-80

°C

and

visualized

with

a

phosphorimager (Storm 860 Molecular Imager).

4.3.10 Kinase assay with Gld2 protein substrate. Gld2 was purified as described
previously (15). 30 µL reaction containing 1.5 µg Gld2 in kinase buffer (20 mM
MOPS [pH 7.0], 25 mM β-glyceraldehydephosphate, 25 mM MgCl2, 5 mM EGTA
[pH 8.0], 1 mM Na2VO4, 0.1 mM ATP, 13.2 nM γ-[32P]-ATP) and Akt1 (33 nM) or
CK2-α (25 nM) kinases were incubated at 37°C shaking for 15 minutes. Samples of
5 µl were taken after 10 minutes and the reaction was stopped by spotting on P81
paper. The P81 paper was washed with 1% phosphoric acid, air dried, exposed to
a phosphor screen over night and visualized with the Storm 860 Molecular Imager.
Purified CK2-α kinase was used as kinase control and was a generous gift from
Dr. David Litchfield.

4.4 Results

4.4.1 Akt1 phosphorylation status alters selectivity among known substrates.
Phosphoinositide dependent kinase (PDK1) site specifically phosphorylates Akt1
at Thr308, while the upstream kinase of S473 is unknown. Using a combination of
genetic code expansion to encode phosphoserine at S473 and co-expression of
PDK1, we were able to produce active full length and PH domain truncated Akt1
variants in E. coli with either or both Thr308 and Ser473 sites phosphorylated
(Figure S4.1, (8,9)). In previous work, we discovered that the traditional
phosphomimetics are incapable of replacing or approximating the functionality of
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phosphorylated Ser and Thr at the activation sites of Akt1 and that alanine
substitutions at these sites also disable the enzyme (8). The significance of our
approach is the ability to generate pAkt1 and ppAkt1 variants without the need
for amino acid substitutions with phosphomimetics.
Our previous studies on pAkt1 and ppAkt1 variants focused on their
differential activity with a single substrate peptide derived from GSK-3β (8). Here
we quantified the substrate preference for phosphorylated Akt1 variants using a
synthetic peptide library of known Akt1 substrates. We found that the deletion of
the PH domain abolishes its auto-inhibitory activity and leads to more soluble
enzyme (9) appropriate for larger scale screening studies presented here.
Currently “known” Akt1 substrates have been identified and in some cases
validated using multiple different experimental approaches, including in vitro
biochemical (22) and cell-based activity assays (23), proteomic analysis (24), as well
as immunoblotting (25) in cells (26) and animals (27).
Our study allowed the evaluation of these distinctively reported substrates
using one systematic platform to quantify Akt1 kinase activity. The doubly
phosphorylated Akt1 was capable of phosphorylating most, but not all, of the
substrate peptides in the library. The ppAkt1 enzyme showed significantly above
background activity with 95% of the peptides tested (Figure 4.1A). In our activity
assays, the initial reaction velocity varied over an 80-fold range; ppAkt1 produced
between 0.1-8.0 pmol/min of phosphorylated peptide.
Overall the level of phosphorylation observed was markedly lower with
pAkt1S473 compared to pAkt1T308 and the ppAkt1T308, S473 (Figure 4.1). Compared to
the singly phosphorylated variants (Figure 4.1BC), ppAkt1T308,

S473

usually

displayed more activity and was active over the widest range of substrate peptides.
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Indeed, we observed a clear trend in activity over the library with pAkt1S473
showing the most restricted substrate range (82% of the library) compared to the
variants phosphorylated at Thr308 (5% of the library) and ppAkt1 (8 % of the
library).
In comparing singly and doubly phosphorylated Akt1, it is clear that the
three variants have distinct preferences for particular peptides. The highest active
substrates for pAkt1S473 variant were completely orthogonal to or distinct from the
most active substrates with pAkt1T308 or ppAkt1T308, S473 (Figure 4.2).
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Figure
4.1 Phosphorylation
known
peptides
Akt1
variants. The

pAkt1S473 Akt1 variants phosphorylated 84 different known substrate derive peptides at the presence of [γ-32P]ATP. Gene names
of each substrates where the peptides synthesis was based on are given in X axis. Phosphorylation sites are given within
brackets for peptides carrying more than phosphorylation site. Error bars represent ± 1 SD.
T308,S473

was significantly above background (ns).
T308

activity (pmol of phosphorylated peptide following a 10 minute reaction) of (A)

pAkt1S473 (B) pAkt1T308 (C) and ppAkt1T308,S473 variants with each of the 84 different

“known” Akt1 substrate derived peptides. Gene names for each substrate are

provided on the horizontal axis. For substrates with multiple phosphorylation

sites, separate peptides were synthesized and are indicated by the phosphorylation

site residue number in parentheses. All experiments were performed in triplicate;

error bars represent ± 1 SD. A minority of the peptides did not support activity that
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The pAkt1S473 variant was most active with substrates (Figure 4.2A) that
were completely distinct from those observed for pAkt1T308 variant. To visualize
these distinct substrate preferences, we generated a Search Tool for Retrieval of
Interacting Genes/Protein (STRING) diagram (28), including nodes representing
all 84 substrates in the library. Overlaid on the STRING diagram we highlighted
the most (>50% activity) and least (< 10% activity) active substrates associated with
each of the Akt1 phospho-forms (Figure 4.2).
The Fork head box O (FOXO) family of transcription factors are wellestablished substrates of Akt1 (25,29). The FOXO family transcription factors were
among the most active substrates with Akt1 phosphorylated only at Thr308.
Indeed, we found that the FOXO target peptides were among the highest activity
for both Akt1 variants phosphorylated at Thr308, pAkt1T308 and ppAkt1T308,S473
(Figure 4.2B, 4.2C). We also observed that while FOXO1 was among the highest
active peptide substrates with pAkt1S473, the enzyme singly phosphorylated at S473
displayed low activity with peptides derived from other FOXO family members.
Certain substrate peptides, e.g., including FOXOs and TSC2, carried more
than one phosphorylation site, which we represented with distinct synthetic
peptides. Each Akt1 phospho-variant showed different preferences for the
multiple sites in these substrates. For example, with pAkt1S473, Ser256 and Ser319
of FOXO1 showed relatively high activity, but this enzyme showed low activity
with a peptide derived from FOXO1 Thr24. In contrast, for both pAkt1T308 and
ppAkt1T308,S473 FOXO1 Ser319 was the least preferred compared to Ser256 and
Thr24.
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A

B

C

Figure 4.2 String diagrams showing the interactions among highly active
peptide substrates of Akt1 variants. (A) Highly active phosphorylated substrates
of pAkt1S473 shared a unique profile, which was not shared by the other two
variants (B) pAkt1T308 variant phosphorylated substrates showed a similar profile
to the doubly phosphorylated variant. (C) Highly active phosphorylated
substrates of ppAkt1T308,S473 included most of the FOXO transcription factors.
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Figure 4.3 Comparison of substrate preferences of ppAkt1T308,S473 with pAkt1T308.
Red bars represent the substrate peptides arranged in increasing order of

Figure 3: Comparison of substrate preferences of ΔPH ppAkt1T308,S473 with ΔPH pAkt1T308. Red bars represent the substrate
peptides arranged in increased order of activity. The corresponding ΔPH pAkt1T308 phosphorylated substrates are shown in blue.
T308given in X axis. Phosphorylation sites are given
Gene namesT308,S473
of each substrates where the peptides synthesis was based on are
within brackets for peptides carrying more than phosphorylation site. Error bars represent ± 1 SD.

ppAkt1

activity. The corresponding pAkt1

phosphorylated substrates are

shown in blue. Gene names of each substrates where the peptides synthesis was
based on are given in X axis. Phosphorylation sites are given within brackets for
peptides carrying more than one phosphorylation site. Error bars represent ±1 SD.

To better understand the impact of Ser473 phosphorylation on the activity
of the doubly phosphorylated Akt1, we plotted kinase activity data of pAkt1T308
and ppAkt1T308,S473 together (Figure 4.3). We analyzed these comparative data for
statistically significant differences. Interestingly, we observed that additional
phosphorylation at Ser473 significantly increased Akt1 activity for many (90%) but
not all Akt1 substrates.
In the context of Akt1 phosphorylated at Thr308, we found that addition of
phosphorylation at Ser473 actually decreased the activity of several competent
Akt1 substrates. Phosphorylation at Ser473 reduces activity for all four peptides
derived from distinct sites in the FOXO4 transcription factor, two distinct sites in
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FOXO1 and FOXO3 as well as sites in cyclin dependent kinase 2 (CDK2), Grb2
associated binding protein (Gab2), CDC like kinase 2 (CLK2), and TSC complex
subunit 2 (TSC2). Together the data show that both regulatory phosphorylation
sites in Akt1 have a significant and unexpectedly complex impact on substrate
selectivity over a library of known Akt1 substrates.

4.4.2 Phosphorylation dependent changes in the Akt1 target motif. Based on the
activity data in Figure 4.1, we computed sequence logos for each Akt1 phosphoform. The logos (Figure 4.4) represent the key residues of importance in
phosphorylation based on the activity level recorded for each substrate peptide
(Figure 4.1). The sequence alignments used to generate the logos was populated
with each of the 84 peptides such that the number of occurrences of each peptide
in the alignment was linearly related to enzyme activity recorded in Figure 4.1.
The importance of conserved consensus sequence residues R-5 and R-3 for
Akt1 substrates (R-5-X-R-3-X-X-S/T) was observed with all three variants. As
reported previously (12), the presence of a large hydrophobic residue following
the phosphorylation site (+1 position) was observed among the peptides with all
three Akt1 variants. Pro occupied the +2 position at the highest frequency in
pAkt1T308 and ppAkt1T308, S473 variants, and the most active substrates tend to have
Pro at +2. The +2 position favors amino acids capable of producing tight turns in
protein structures. According to Obata and others Gly, Ser, Asn and Thr were also
found to be favorable at this position (13). Peptide substrates showing high activity
with pAkt1S473 variant were dominated by those peptides with a Ser rather than a
Thr at the phosphorylation site. For pAkt1T308 and ppAkt1T308,S473, highly active
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peptides were approximately equally likely to have Ser or Thr at the
phosphorylation site.

4.4.3 Alanine scanning of Akt1 target peptides. To provide additional data
regarding essential amino acid residues for kinase activity with each
phosphorylated Akt1 variant, we next synthesized peptides containing alanine
substitutions at each position in the consensus motif (Figure 4.4). The consensus
motif was derived from the activity data on the known substrates (Figure 4.1). For
these studies, we chose a peptide derived from GSK-3β. Among known substrates,
GSK-3β shows significant activity (>50% maximal) with each Akt1 phospho-form
(Figure 4.1); peptides derived from GSK-3β are commonly used to assess Akt
activity (8,12).
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Figure 4.4 Sequence logos representing the amino acid preferences adjacent to
the
Akt1 target motif. Sequence logos of (A) pAkt1S473 phosphorylated (B) pAkt1T308
Figure 4: Web-logos representing the amino acid preferences of the phosphorylation site of Akt1 substrates. Enzyme variants
S473

T308

T308,S473

of (A) ΔPH pAkt1
phosphorylated (B) ΔPH pAkt1
phosphorylated and (C) ΔPH ppAkt1
phosphorylated substrates
S473
phosphorylated
andThe
(C)phosphorylation
ppAkt1T308,
are bybased
on enzyme activity
data in Figure
were used to create the logos.
site is denoted
#0 in x axis.

4.1 as described in methods. The phosphorylation site is denoted by the 0 position.
Sequence logos were created using the WebLogo server (18).
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The pAkt1T308 and ppAkt1T308,S473 variants showed a similar response to each
of the alanine substituted peptides, whereas the pAkt1S473 response was distinct
(Figure 4.5). For each Akt1 variant, alanine mutation at the phosphorylation site
abolished the enzyme activity to a level indistinguishable from background. R-3
was essential for all three variants to be active. Arginine at -5 was important for
pAkt1S473 activity, where an alanine substitution lead to only 0.4 pmol/min activity,
a 9-fold reduction. pAkt1T308 did not show a significant (p<0.05) difference with the
control at arginine -5, where in contrast, ppAktT308, S473 showed a 0.8-fold increased
activity in comparison to the control peptide. Attesting to the robust activity of the
ppAkt1 enzyme according to our previous studies, ppAkt1 displays higher activity
for each Ala substitute peptide compared to the singly phosphorylated enzymes.

4.4.4 Determination of high-resolution Akt1 target specificity. Our analysis of
known substrates revealed several new facets of Akt1 enzymology, however, these
data are biased by our current and perhaps limited knowledge of Akt1 substrate
selectivity on 84 previously identified Akt1 substrates. We, therefore, designed a
far larger, unbiased oriented library of peptides to test the most preferred amino
acid residue at each site of the Akt1 substrate consensus motif. We synthesized 128
different pools of peptide sub-libraries (see Methods) to cover the complete library
of 1011 peptides. Using each phospho-form of Akt1, we conducted kinase assays
with each of the substrate sub-libraries (Figures S4.1, S4.2, S4.3). In each sub-library
a single amino acid is held constant for a single position in the consensus, while all
other variable positions are allowed to cover the complete sequence space with the
exception of Cys, Thr and Ser. The Akt1 activity for singly and doubly
phosphorylated Akt1 variants over each peptide sub-library pools are shown in
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terms of activity and overlaid as a heat map indicating relative changes in activity
(Figure 4.6).
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Figure 4.5 Alanine scanning of each residue in the GSK-3β derived peptide.
Corresponding peptide sequences are shown adjacent to the activities for each
indicated Akt1 phospho-form. The ‘wild-type’ and unmutated control peptide is
bolded. Akt1 activity is presented as absolute activity values (pmol ppeptide/min). Statistically significant changes in comparison to the ‘wild-type’
unmutated peptide control are indicated as p < 0.05 (*) or p < 0.01 (**).

To visualize the amino acid preferences and anti-determinants we
converted the activity data into PSSMs (see Methods). Using Seq2Logo (19) we
generated sequence logos representing the OPAL data (Figure 4.7). The results
clearly demonstrate that the substrate selectivity of pAkt1S473 is both more
restricted and totally distinct from the profile we observed for the pAkt1T308 and
ppAkt1T308,

S473

enzymes. Both ppAkt1T308,

S473

and pAkt1T308 preferred large

hydrophobic residues (Phe, Tyr, Trp) at the +1 position in the target peptide. In
contrast, pAkt1S473 prefers basic residues (Lys, Arg, His) at the +1 position. Ile at -1
and +2 positions were the least favorable for both pAkt1T308 and ppAkt1T308,S473
variants. Phe and Pro are least preferred at -1 and +2 positions for pAkt1S473. The
least preferred amino acid cluster at position +1 include Pro, Asp, Glu and Gly for
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pAkt1T308 and ppAkt1T308, S473. Thus the least favoured cluster for pAkt1S473 include
Asp, Asn, Gln and Pro. Finally, we note that the specific amino acids most
preferred at each position is distinct between each Akt1 phospho-form (Figure 4.6,
4.7) in concordance with the unique substrate selective profiles we recoded over
the library of known substrates (Figure 4.1).
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activity values from Figure 4.6 into a PSSM. Seq2Logo was used to convert the
PSSMs to amino acid preferences as represented by sequence information bits.

Next, we used information from the OPAL experiments to score the known
human phospho-proteome to identify new Akt1 substrates. We then converted the
Akt1 activity data into PSSMs based on calculating z-scores (see Methods) as
before (14). The known human phospho-proteome was scored based on the amino
acid preferences at each position in the z-score PSSM (Table S4.1). The scoring of
peptides was performed for data based on each phospho-form of Akt1. We then
selected the top scoring substrates (normalized sum of z-scores > 3). We included
all of these high confidence hits in a STRING diagram to identify potential protein
interactions and functional clusters among the known and predicted substrates
(Figure 4.8, Table S4.1).
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Figure 4.8 Interactions among highly active known and novel substrates of Akt1
variants derived from OPAL screen. (A) String diagram of interactions and (B)
GO enrichment analysis conducted using Gene Ontology (30) for the string
diagram are shown. Red, yellow and green colors are assigned for novel substrates
identified for pAkt1T308, pAkt1S473 and ppAkt1T308,S473 variants, respectively. Blue
color denoted known substrates for ppAkt1T308,S473. Novel clusters of substrates
involved in cell division, (orange), translation (blue), cytoskeleton (purple), RNA
processing, lipid signaling, chromatin and processing (three gray circles) are
encircled.
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The search identified both known and unknown Akt1 substrates among the
high confidence hits. Interestingly, the prediction suggested the presence of Akt1
substrate in pathways not previously known to be regulated by Akt1. These
include clusters of proteins that participate in translation, transcription, cell
division, cytoskeletal organization, and lipid signaling (Figure 4.8A). The putative
Akt1 substrates are significantly enriched in gene ontology (GO) (30) molecular
functions related to protein kinases, RNA binding, and cytoskeletal organization
according to GO enrichment analysis (Figure 4.8B). Putative Akt1 substrates
include centromeric proteins involved in cellular mitosis. Chromosome associated
protein G, boreilin, opa protein 5 and centromere protein O were the identified
strong candidates for activity with each phospho-form of Akt1. Another novel
cluster of putative Akt1 targets includes nucleolar proteins involved in ribosomal
RNA processing. RNA binding motif protein 34, nucleolar protein 10, E3 ubiquitin
ligase (RB binding protein 6 ubiquitin ligase) and RNA helicase were among this
functional cluster.

4.4.5 Akt1 variants differentially phosphorylate NIH 3T3 cellular proteins. We
next measured the overall activity of each Akt1 phospho-form using the soluble
cellular proteome derived from mammalian cells. We incubated the Akt1 variants
with NIH 3T3 cell extracts to quantify how Akt1 phosphorylation status impacts
its kinase activity on natural and full-length protein substrates. The reactions and
controls contained γ-[32P]-ATP. The phosphorylated cell extracts were separated
on SDS-PAGE gels and exposed to a phosphor-imaging screen to quantify radiolabeled proteins. Significant activity was observed with the ppAkt1T308,S473 and
pAkt1T308 variants (Figure 4.9). In agreement with the peptide experiments,
pAkt1S473 demonstrated low activity with cellular extracts. The enzyme with a
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single phosphorylation at Thr308 nearly reaches the maximal activity observed
with the ppAkt1T308, S473 enzyme, validating our previous findings in COS7 cells
(Chapter 2, (8) ).
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Figure 4.9 NIH 3T3 cell lysates were incubated with the indicated Akt1
phosphorylated variants and 𝛾-[32P]-ATP. At specified time point, the reactions
were quenched and (A) visualized 10% SDS-PAGE gel and exposed to phosphorimaging screen. (B) The radiolabeled protein intensities were quantified based on
duplicate measurements.

4.4.6 Validation of a novel Akt1 substrate. One of the novel potential substrates
of Akt1 derived from the OPAL scan was the nucleotidyltransferase Gld2. Gld2
adenylates miRNAs and mRNAs to increase their stability, which impacts gene
expression (31). We used doubly phosphorylated Akt1 to test Akt1 activity on
recombinantly purified Gld2 in vitro. In comparison to CK2-α, which showed no
significant activity, Akt1 and protein kinase A (PKA) efficiently phosphorylated
Gld2 (Figure 4.10, S4.4). These data were including in our recent publication (15).
Mass spectrometry results revealed that ppAkt1 phosphorylated Gld2 specifically
at Ser116 (Figure 4.11) (15). We also found that the Gld2 Ser116Ala mutant was not
a substrate for Akt1 (15). The data demonstrate that Akt1 site-specifically
phosphorylates Gld2 at Ser116. Strikingly, as found by my colleagues,
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phosphorylation at this site nearly abolishes Gld2’s ability to catalyze nucleotide
addition to microRNAs and mRNAs (15). The data suggest Akt1-dependent
phosphorylation may be a powerful mechanism to regulate mRNA and miRNA
metabolism.

phosphorylated Gld2 (fmol)

14

ppAkt1 + Gld2

12
10
8
6
4

ppAkt1 (auto-phosphorylation)
Gld2 + CK2-!
No enzyme (-Gld2, -Akt1)
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Figure 4.10 Kinase activity assays of Akt1 and CK2-α with Gld2 protein
substrate. The enzyme activity was plotted over time. Akt1 but not CK2-α showed
significantly increased reaction velocity with Gld2 as a substrate. All reactions
were performed in triplicate (see Figure S4.4).
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Figure 4.11 Akt1 and PKA phosphorylate Gld2 at S116. Mass spectra of
unphosphorylated Gld2 after incubation with CK2-α and phosphorylated after
incubation with ppAkt1T308,S473 or PKA. Unphosphorylated peptide is indicated by
the light pink peak and the phosphorylated peptide by the dark peak. Position 116
is bolded and underlined (15).

4.5 Discussion
We recently developed a new method to produce Akt1 with programmed
phosphorylation at either or both key regulatory sites (8). This breakthrough
technology enabled resolution of the contribution of each phospho-site to the
activation (8) or inhibition (9) of Akt1. Because this approach was only recently
developed, there are still very few studies that report on the function or impact of
each phosphorylation site on Akt1 substrate specificity (32). Investigations into the
substrate specificity of Akt have focused on characterizing the isozyme specific
substrate preferences that differ between Akt1, Akt2, and Akt3 (1,33). Indeed, the
previous lack of tools to isolate the function of each Akt1 phospho-form inhibited
investigations to characterize the impact of each phosphorylation site on substrate
specificity. Our approach to produce singly and doubly phosphorylated Akt1
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variants using genetic code expansion with or without co-expression of the
upstream kinase PDK1 has to overcome this technological barrier (8,9).

4.5.1 Phosphorylation dependent substrate specificity of Akt1. In our previous
studies (8), we found that phosphorylation at Thr308 was necessary and sufficient
for maximal Akt1 activity in mammalian cells. The addition or ablation of Ser473
had some impact on the activity of the kinase in the test tube but did not influence
phosphorylation of an Akt-specific live cell fluorescent reporter (8). These
observations lead to our hypothesis that phosphorylation of Ser473 may function
to tune rather than activate the Akt1.
Using peptide library approaches, we mapped the substrate preferences for
each key phospho-form of Akt1. The data presented here revealed that Ser473
phosphorylation does indeed impact substrate specificity. More generally, we
found that the phosphorylation status of Akt1 has a global impact on substrate
preference as determined by kinase activity.
A multitude of studies (34,35), including our own (8) have presented
evidence indicating that Akt1 activity increases monotonically with pAkt1S473 <
pAkt1T308 < ppAkt1. Based on all of our assays, it remains clear that the pAkt1S473
enzyme is far less active than the other two. Of the 84 known substrates we tested,
this rule only holds completely true for half of the peptides (49%). When
comparing pAktT308 with ppAkt1T308, S473, we found that many substrates (48%) show
the same level of activity with pAkt1T308 and ppAkt1, while a minority (3%) are
actually more active with the singly phosphorylated pAkt1T308 compared with the
doubly phosphorylated enzyme.
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Our current study further revealed that when only Ser473 is
phosphorylated the substrate preference profile is distinct in comparison to Thr308
phosphorylation. This observation was supported by data generated from ‘known’
substrates as well as the much larger data set generated using the OPAL approach.
Several highest active substrates for pAktS473, including MDM2 (Ser188), MDM4,
EP300 and eNOS (S1177), are members of the p53 mediated apoptotic pathway (36)
(Figure 4.2A). Phosphorylation of MDM family members and EP300 by Akt1 leads
to p53 ubiquitination and degradation and promotes cell survival (36). Akt
phosphorylates eNOS, which enhances its activity to produce nitric oxide (NO)
(37). Acting as a signaling molecule, NO promotes angiogenesis in tumors (38),
however, NO plays a dual role in cancer cell survival (37). Under oxidative stress
induced cellular environment, NO promotes accumulation of p53 in the nucleus
leading to apoptosis (38). p53 activates phosphatase and tensin homolog (PTEN)
which is the phosphatase responsible in dephosphorylating the Akt binding lipid
second messenger phosphatidylinositol-4, 5-triphosphate (PIP3) which suppresses
Akt activation (39).
The significance of Ser473 phosphorylation in differential substrate
phosphorylation had been highlighted anecdotally. Jacinto et al. (2006) found
disruption of Ser473 phosphorylation resulted from genetic ablation of sin1. Sin1
is a component of the TORC2 complex, which phosphorylates Ser473. In mice or
mammalian cells, downstream Akt1 substrate phosphorylation events were
subsequently down regulated in a subset of Akt1 substrates, which included
FOXO1 and FOXO3 (32). Indeed, although many substrates do not show different
activity with ppAkt1T308,S473 versus pAktT308, all of the FOXO peptides except the Nterminal phosphorylation sites T24 and T32 of FOXO1 and FOXO3, respectively
showed loss of activity in the absence of pS473 phosphorylation (Figure 4.2, 4.3).
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The next example is related to endoplasmic reticulum stress in mammalian
cells. Upon ER stress, the ER chaperone protein GRP78 is down regulated and this
leads to increased phosphorylation of Akt1 at Ser473 but not Thr308 in JEG3 cells.
As a result, increased Akt1-dependent phosphorylation of HDM2 (pSer166),
FOXO1 (pSer319) and GSK3-β (pSer9) were observed by Western blotting (40). In
our study, FOXO1, FOXO3 and GSK3-β demonstrated higher activity with both
ppAkt1T308, S473 and pAkt1T308 variants in comparison to pAkt1S473 (Figure 4.2, Figure
4.3).
Our data clearly indicate that ppAkt1 is normally (but not always) more
active and has a broader substrate profile than either of the singly phosphorylated
enzymes. In alignment with the essentiality of pThr308 in the activation of Akt1 in
vitro and in cells (8,35), we found that the two variants phosphorylated at T308
showed greatest similarities in substrate preferences in comparison to the pAkt1S473
enzyme. Manning and Cantley (2007) observed that Ser473 was not essential for
phosphorylating the non-N-terminal phospho-sites of the FOXO transcription
factors, TSC2, or GSK-3β (10). These observations are in close agreement with and
supportive of our findings. The ppAkt1T308, S473 enzyme showed high activity with
FOXO1 C-terminal phosphorylation sites (S319, S256), TSC2 and GSK-3β (Figure
4.2, Figure 4.3). For pAkt1T308, all three FOXO1 phospho-sites ranked among the
highest active substrates, suggesting that Ser473 is not a critical factor in FOXO1
phosphorylation. In the clinic, phosphorylation of Thr308 was associated with
poor cell survival with non-small cell lung cancer (41) and acute myeloid leukemia
(42). According to our data here (8), we suggest that phosphorylation of Thr308
alone may be capable of switching-on downstream signaling to promote cell
survival by inhibiting the FOXO group of transcription factors. High level of
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phosphorylation of Thr308 could contribute to the poor survival rate of lung cancer
(38) and leukemic patients (39) with tumors characterized by hyper-active Akt1.

4.5.2 Phosphorylation dependent changes in the Akt1 substrate motif. The
molecular basis for kinase substrate selectivity depends on the residues
neighboring the phosphorylation site (13). Yet it is important to understand that
not all substrates identified for Akt isozymes include the same consensus motif
(10). In the context of the cell, even with an optimal substrate according to the
consensus motif requirements, phosphorylation by Akt1 will depend on multiple
factors, including accessibility, cellular localization, and phosphatase activity (11).
Our data obtained from the OPAL study for ppAkt1T308, S473 was in accord
with but extended beyond previously reported results (12,13). We fixed the -3
position to an Arg since the essentiality of Arg at -3 is well established (13).
According to our results, all Akt1 phospho-forms showed a preference for Arg at
position -5. ppAkt1T308, S473 and pAkt1T308 showed preference for hydrophobic amino
acids for position +1. These amino acid preferences are shared by other AGC family
kinases including protein kinase C. Obata et al. (2000) used degenerative peptide
library studies to determine the most relevant substrate motif for active Akt1 (13).
Unlike in our study, active Akt1 was derived from SF-9 insect cells and the
phosphorylation status of Akt1 enzyme was not precisely defined. The authors
reported the amino acid preferences derived from a set of known substrates and a
degenerative peptide library. In comparison with these sequence preferences, we
observed a strong compatibility with the predicted residues of our OPAL results
with positions -5 and +1 with pAkt1T308 and ppAkt1T308, S473. The most preferred
amino acid at the -5 position was Arg and preferred amino acids at +1 are large
hydrophobic residues. Both pAkt1T308 and ppAkt1T308, S473 enzyme variants showed
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preference for Phe at position -6 as observed in the generative library predictions
of Obata et al. Lys and Arg were predicted to be preferred for position -4 according
to our OPAL results. According to their predictions position -4 could be any amino
acid. In contrast to the study by Obata et al, we observed no selection for Ser and
Thr at +2 with our OPAL data. Thus, Ser and Thr at +2 were the favorable amino
acids according to our known library data.

4.5.3 Putative substrates derived from OPAL screening. OPAL data lead to a
predicted consensus sequence for all three Akt1 variants (Figure 4.7). These
predicted consensus sequences were matched against the human proteome to
identify potential novel substrates. Zn finger domain carrying proteins (numbered
211, 251, 484, 668, 773, 792, 835) were abundant among the most likely putative
Akt1 substrates. The functionality of Zn fingers includes DNA and/or RNA
binding, protein-protein interactions and membrane binding. Indeed, most
transcription factors carry Zn finger (43). Since Akt is well known for its
phosphorylation-based inactivation of transcription factors like FOXO family
proteins, Zn fingers containing transcription factors are interesting potential
targets of Akt1.
Validation of predictions based on our biochemical data using cellular or
ultimately animal models is warranted in future studies. Our initial investigations
towards such validations revealed that the E. coli produced Akt1 variants can
phosphorylate cellular substrates (Figure 4.9). Next, based on the OPAL
predictions we found that Akt1 may be involved in regulating RNA metabolism
(Figure 4.8). Gld2, which is a nucleotidyltransferase that regulates RNA stability
was one of the predicted targets of ppAkt1T308,S473. Gld2 has been implicated in the
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stabilization and maturation of the tumour suppressor microRNAs miR-122 and
let-7 (44,45). We found Gld2 was specifically phosphorylated by Akt1 at Ser116,
which abolished Gld2 activity in 3’-terminal addition of adenine to miRNA and
mRNA substrates (15). As hyperactivity of Akt1 is common in many cancers (46),
our results suggest that phosphorylation of Gld2 by Akt1 would be beneficial for
cancer cells in order to decrease the levels of miRNAs that act as tumour
suppressors such as miR-122 and let-7 (15). Our data, thus, suggest a novel role of
Akt1 activity on a miRNA editing enzyme and provides the first link between
tumor suppressor miRNA regulation and oncogenic signaling.

4.6 Conclusion
The phosphorylation status of Akt is a commonly used biomarker for
human cancer (41). Here we found that Akt1 phosphorylation status has a global
impact on substrate selectivity. Fascinatingly, ppAkt1T308,S473 showed higher activity
with most but not all substrates compared to Akt1 singly phosphorylated at
Thr308. Indeed, a select pool of substrates was highly active with pAkt1T308. The
pAkt1S473 variant had a distinct substrate preference profile compared to Akt1
variants phosphorylated at Thr308. The role of Ser473 phosphorylation appears to
involve global tuning of substrate selectivity rather than in truly activating the
kinase. Indeed, it remains unknown whether Akt1 with only Ser473
phosphorylated is active in the cell (8,35). Our findings have major implications
for the use of Akt1 phosphorylation status as a clinical diagnostic (41,47) or a
marker for cancer biology (46).
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4.8 Supporting Information
Table S4.1 OPAL predictions of known and unknown Akt1 substrates
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Figure S4.2 Autoradiographs on OPAL assay conducted for pAktS473. Ax-Hx are
sub-library pools of peptides where one amino acid has kept unchanged in the
peptide sequence while the rest is randomized with 17 amino acids except serine,
threonine and cysteine.Assays were performed in triplicate (as indicated by R1R3). Controls include: C1 enzyme without substrate peptide, C2 only kinase assay
buffer.
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Figure S4.3 Autoradiographs on OPAL assay conducted for pAktT308. Ax-Hx are
sub-library pools of peptides where one amino acid has kept unchanged in the
peptide sequence while the rest is randomized with 17 amino acids except serine,
threonine and cysteine. Assays were performed in triplicate (as indicated by R1R3). Controls include: C1 enzyme without substrate peptide, C2 only kinase assay
buffer.
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Figure S4.4 Autoradiographs on OPAL assay conducted for ppAktT308, S473. Ax-Hx
are sub-library pools of peptides where one amino acid has kept unchanged in the
peptide sequence while the rest is randomized with 17 amino acids except serine,
threonine and cysteine. Assays were performed in triplicate (as indicated by R1R3). Controls include: C1 enzyme without substrate peptide, C2 only kinase assay
buffer.
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Figure S4.5 Kinase activity assays of Akt1 and CK2-α with GLD2 and 𝛾-[32P]ATP as substrates. Spot pictures of the activity assays where the reactions were
spotted at 5, 10, 15 min time points. The data are plotted in Figure 4.10.
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Chapter 5

5 Summary and future perspectives

5.1 Summary
The proto-oncogene Akt/PKB is a key regulatory kinase in the PI3K/Akt cell
survival pathway and belongs to the AGC family of kinase (1). There are three
isozymes of Akt named Akt1, Akt2 and Akt3. All three isozymes are activated
upon growth factor stimulation (2). In Akt1, Thr308 and Ser473 are the key
regulatory phosphorylation sites. Following activation by receptor tyrosine
kinases at the plasma membrane, phosphoinositide-3-phosphate kinase (PI3K)
phosphorylates its immediate downstream target, a lipid second messenger called
phosphatidylinositol-4,

5-bisphosphate

(PIP2),

converting

PIP2

into

phosphatidylinositol-4, 5-triphosphate (PIP3) (1,3). PIP3 harbors binding sites for
PH domain carrying proteins like Akt and PDK1. Co-localization of PDK1 with
Akt at the plasma membrane promotes phosphorylation of Thr308 by PDK1 (1).
The second site Ser473 in the regulatory domain of Akt is phosphorylated by
mechanistic target of rapamycin complex 2 (mTORC2).
Once the activation via phosphorylation is complete, Akt dissociates from
the plasma membrane and is transported to the cytosol and nucleus to
phosphorylate additional downstream target substrates (1,3). The mechanism of
activation of Akt is well-studied, however, the contribution of each
phosphorylation site to the activation of Akt1 remained elusive. Technical
difficulties associated with producing single site phosphorylated variants
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hindered the characterization of the functionality of each phosphorylation site.
This phosphorylation status of Akt1 is clinically relevant as in multiple different
types of cancer the level of phosphorylation of each activation site in Akt has been
linked with the survival rate of cancer patients (4).
In my initial experiments, my goal was to determine the contribution of
each regulatory phosphorylation site to the overall activation of the Akt1 kinase.
In this first objective, I used a genetic code expansion strategy in a novel
combination with enzymatic phosphorylation to produce site-specifically
phosphorylated Akt1 variants (5). Using these two methods, we produced singly
phosphorylated Akt1 variants recombinantly in E. coli and confirmed the presence
of phosphorylation at each site using mass spectrometry and activity assays. We
compared the activity of the unphosphorylated, singly phosphorylated and
doubly phosphorylated Akt1 variants using radioactive kinase assays with a Akt1
substrate peptide derived from GSK-3β. The apparent catalytic rate of the kinase
when both activation sites are phosphorylated was 1500-fold higher than the
unphosphorylated Akt1. The contribution of Thr308 in activation of Akt1 was only
reduced from the doubly phosphorylated enzyme by ~3-fold and was significantly
more active than pAkt1S473. Live-cell imaging in COS7 cells further confirmed that
phosphorylation of Thr308 was sufficient and irreplaceable for Akt activation in
cell (5).
The traditional method of using phosphomimetics substitutions, such as
Glu and Asp mutations, to mimic phosphorylation was also tested (6). In both the
test tube and in mammalian cells, phosphomimetics failed to activate the kinase in
comparison to true phosphorylation. Mutation of Thr308Ala produced a kinase
dead mutant, which is not active in vitro despite of the phosphorylation at Ser473.
In in vitro kinase assays and in COS7 cells, Akt1 Thr308Ser was a partially
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activated kinase, revealing a critical interaction between the γ-methyl group of
Thr308 and Cys310 in the activation site of Akt1 (5).
Once the contribution of each phosphorylation site on activation of Akt1
was determined, next I investigated the impact of each phosphorylation site on
releasing the auto-inhibitory effect of the PH domain of Akt1 (7). I used the same
experimental strategies noted above to produce Akt1 variants without the PH
domain. Deletion of PH domain increased the enzyme activity of all Akt1 variants.
Presence of PH domain has inhibited doubly phosphorylated Akt1 by a factor of
29-fold compared to the non-phosphorylated enzyme and the two singly
phosphorylated variants i.e. pAkt1T308 and pAkt1S473 , were inhibited by factors of
17-fold and 5-fold, respectively.
Next, I tested the impact of Akt1 phosphorylation status on chemical
inhibition. A known PH domain dependent Akt inhibitor, Aki1/2 was used (8).
Our results showed that phosphorylation at Ser473 provided resistance to Akt
inhibition, increasing the IC50 by 4-fold. These findings highlight the importance of
selecting the most pathogenic form of the kinase in designing potent inhibitors for
Akt1 (7).
The impact of Akt1 phosphorylation status on substrate selectivity was
unknown. A few reports have suggested a role for Akt1 phosphorylation status in
modulating substrate selectivity (1,9), yet no systematic investigation has been
conducted. We, therefore, used peptide library based approaches to investigate the
substrate selectivity of singly and doubly phosphorylated Akt variants.
We found that Akt1 p-status has a global impact on substrate selectivity.
The pAktS473 enzyme has a completely different substrate selectivity profile
compared to pAkt1T308 or ppAkt1. Amazingly, the doubly phosphorylated
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enzyme is usually, but not always more active than pAkt1T308. The role of S473
phosphorylation appears to be involve in globally tuning substrate selectivity
rather than activating the kinase. From the predicted substrates we verified that
the terminal nucleotidyltransferase (germline development 2) Gld2 was
phosphorylated at specifically in its N-terminal domain at Ser116. Phosphorylation
at Ser116 abolished nucleotide addition activity of GLD2 (10).

5.2 Future directions
5.2.1 Validation of predicted substrates
We developed a new method to produce Akt1 with programmed
phosphorylation on each activation site. Although the scientific literature on Akt
is vast, previously, very few studies (9) reported on the specific functionality of
each phosphorylation site or the relationship between Akt1 phosphorylation status,
inhibition and substrate specificity. Most previous studies used protein with
mixed or non-homogenous phosphorylation status. Although such a kinase is
active it can not reveal the role of each phosphorylation site. Since acidic or alanine
substitutions at 308 and 473 alter the activity of this enzyme in the test tube and in
cells (5) such substitutions do not report on the activity caused by actual
phosphorylation. We have been using a systemic approach to cautiously compare
and contrast the phosphorylation site dependent substrate specificity.
The peptide library analysis (Chapter 4) revealed that the phosphorylation
status of Akt1 modulates substrate specificity on a global or proteome-wide scale.
Based on data from the OPAL screen, we were able to identify potential novel
substrates for Akt1. One of the key areas of future directions is validation of these
predictions. Although the data I have produced alone is not sufficient to validate
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these predictions, in vitro activity assays are an essential starting point to prove
the ability of Akt1 to phosphorylate a particular substrate. In the cell, the ability of
Akt1 to phosphorylate a particular substrate is more complex and will rely on the
accessibility, secondary interactions with the kinase, cellular localization and the
physiological status of the cell (3). De-phosphorylation of putative Akt1 substrates
by phosphatases (3) is another complicating factor.

5.2.2 Targeting Akt1 in cancer treatment
The significance of Akt activation in cancer has been widely studied during
the past decades due to the prominent role of Akt in cell growth and survival
(11,12). In cancer cells, Akt is found to be over-activated and hyperphosphorylated, which helps cancer cells to survive (11,13). Therefore, Akt is a
prominent target in developing anti-cancer drugs. Clinical trials to test Akt
inhibitors are currently in progress (14,15), yet a unique anticancer agent for Akt
isozymes has not been successfully designed.
My studies have wide ranging implications for Akt1 drug design as my data
suggests that the phosphorylation status of Akt1 impacts is activity, substrate
selectivity and its ability to be inhibited. The fact that each Akt1 phospho-form has
distinct substrate preferences, indicates that the phospho-forms can be targeted
separately. The site-specifically phosphorylated Akt variants are, thus, invaluable
tools for drug screening and design. These site-specifically programmed kinase
variants will help to make precise inhibitor screening platforms for Akt and
ultimately any human kinase of interest.
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5.3 Conclusion
Using genetic code expansion and co-expression of a specific upstream
kinase, I produced site-specifically phosphorylated Akt1 variants. These variants
are indispensable tools that I used to characterize the functionality of each site
separately and in combination. These Akt1 phospho-variants were instrumental in
my investigations of the activation, auto-inhibition, chemical inhibition and
substrate selectivity of Akt1. Isolating the effect of each phosphorylating site
allowed a detailed characterization of the individual and unique functional roles
of each site in activating a major human kinase linked to cancer.
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